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Deregulated expression of MYC induces a depen-
dence on the NUAK1 kinase, but the molecular
mechanisms underlying this dependence have not
been fully clarified. Here, we show that NUAK1 is a
predominantly nuclear protein that associates with
a network of nuclear protein phosphatase 1 (PP1) in-
teractors and that PNUTS, a nuclear regulatory sub-
unit of PP1, is phosphorylated by NUAK1. Both
NUAK1 and PNUTS associate with the splicing ma-
chinery. Inhibition of NUAK1 abolishes chromatin as-
sociation of PNUTS, reduces spliceosome activity,
and suppresses nascent RNA synthesis. Activation
of MYC does not bypass the requirement for
NUAK1 for spliceosome activity but significantly at-
tenuates transcription inhibition. Consequently,
NUAK1 inhibition in MYC-transformed cells induces
global accumulation of RNAPII both at the pause
site and at the first exon-intron boundary but does
not increase mRNA synthesis. We suggest that
NUAK1 inhibition in the presence of deregulated
MYC traps non-productive RNAPII because of the
absence of correctly assembled spliceosomes.
INTRODUCTION
The MYC oncoprotein is a transcription factor that regulates
broad programs of gene expression, promoting cell proliferation
and cell growth and inducing major changes in growth-associ-
ated processes such as cellular metabolism and the interaction1322 Molecular Cell 77, 1322–1339, March 19, 2020 ª 2020 The Auth
This is an open access article under the CC BY license (http://creativeof cells with the micro-environment (Dang, 2012; Kress et al.,
2015). MYC proteins are almost universally present at active
core promoters. Proteomic analyses show that MYC and its
paralog MYCN affect the function of RNA polymerase II (RNAPII)
via multiple distinct protein complexes (Baluapuri et al., 2019;
B€uchel et al., 2017; Kalkat et al., 2018). MYC proteins can
enhance recruitment of RNAPII to promoters (de Pretis et al.,
2017), promoter escape (B€uchel et al., 2017), release of RNAPII
from the pause site (Rahl et al., 2010; Walz et al., 2014), and
RNAPII processivity during elongation (Baluapuri et al., 2019).
MYCN can suppress the accumulation of promoter-proximal
R-loops and the recruitment of mRNA de-capping complexes,
which terminate transcription at the pause site (Brannan et al.,
2012; Herold et al., 2019).
Cells and tumors expressing deregulated levels of MYC rely
on a number of specific factors for survival, including an
enhanced dependence on anti-apoptotic proteins and trophic
signals (Pelengaris et al., 2002), on glutamine as a nutrient
source (Gao et al., 2009; Xiang et al., 2015), on splicing factors
(Hsu et al., 2015), on cyclin-dependent kinases (Chipumuro
et al., 2014; Christensen et al., 2014; Huang et al., 2014), and
on AMP-dependent kinase (AMPK), which is activated by an
increase in cellular AMP levels (Kfoury et al., 2018; Liu et al.,
2012). The analysis of these dependencies has produced critical
insights into the process of MYC-driven oncogenic transforma-
tion and led to new approaches to selectively eradicate MYC-
driven tumor cells for therapy (Dang, 2016; Haikala et al.,
2019). Cells expressing deregulated levels of MYC also depend
on the AMPK-related kinase NUAK1 (also known as ARK5,
AMPK-related kinase 5) (Liu et al., 2012; Monteverde et al.,
2018). Likewise, colon tumors, which express high MYC levels
because of loss-of-function mutations in the APC tumor sup-
pressor gene, depend on NUAK1 for tumor growth and mainte-
nance (Port et al., 2018). Several explanations have been putors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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Figure 1. NUAK1 Binds to Chromatin and Interacts with a Nuclear PP1 Network
(A) U2OS cells stained for endogenous NUAK1 and PPP1CB. DAPI is used as nuclear counterstain (n = 3; in all legends, n indicates the number of independent
biological replicates).
(B) Immunoblot of fractionation of U2OS cells probed with the indicated antibodies. Ten percent of cytoplasm and nucleoplasm fractions were loaded. RNAPII
(chromatin) and TUBA1A (cytoplasm) were used as localization controls (n = 3).
(C) Immunofluorescence of U2OS cells stably expressing HA-tagged NUAK1 stained with a-HA and a-MYPT1 antibodies (n = 3).
(D) Cell fractionation of U2OS cells stably expressing HA-tagged NUAK1. Ten percent of cytoplasm and nucleoplasm fractions were loaded. RNAPII and TUBA1A
were used as controls (n = 3).
(legend continued on next page)
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forward to explain this dependence; for example, NUAK1 has
been linked to cellular energy metabolism (Liu et al., 2012), to
p53 function (Hou et al., 2011), and to responses to oxidative
stress (Port et al., 2018), which affect the nuclear localization of
NUAK1 (Palma et al., 2019). Nevertheless, the biochemical pro-
cesses that establish the dependence of MYC-overexpressing
cells on NUAK1 are not as clear as for the other dependencies
described above.
A well-established function of NUAK1 is to control the activity
of protein phosphatase 1 (PP1) (Zago´rska et al., 2010). PP1 ho-
loenzymes consist of a broadly active catalytic core (encoded by
one of three highly homologous genes: PPP1CA, PPP1CB, or
PPP1CC) and one of many regulatory subunits (Verbinnen
et al., 2017). Regulatory subunits can both target the PP1 holo-
enzyme to specific compartments in a cell and control its cata-
lytic activity (e.g., some subunits inhibit PP1 activity toward
specific substrates) (Verbinnen et al., 2017). In the cytoplasm,
a major regulatory subunit of PP1 is MYPT1 (myosin phospha-
tase target subunit 1, encoded by the gene PPP1R12A), which
regulates the interaction of actin and myosin (Matsumura and
Hartshorne, 2008). NUAK1 directly interacts with PPP1CB and
forms a trimeric complex with PPP1CB andMYPT1. In the trimer,
NUAK1 phosphorylates MYPT1 and promotes association of
MYPT1with 14-3-3 proteins (Zago´rska et al., 2010). This reaction
blocks the interaction of MYPT1 and PP1with myosin light-chain
kinase (MLC2), increases phosphorylation of MLC2, and thereby
activates myosin II. The MYPT1/NUAK1 interplay also regulates
the activity of Polo-like kinase (PLK1) throughout the cell cycle
(Banerjee et al., 2014b; Werle et al., 2014) and controls AKT-
dependent phosphorylation of GSK3b (Port et al., 2018).
Whether NUAK1 has similar roles on other PP1 holoenzymes in
a cell is unknown.
Here we show that NUAK1 complexes with PP1 in the nucleus
and promotes spliceosome activity. NUAK1 and PP1 are
involved in a regulatory circuit that couples transcriptional elon-
gation to spliceosome activity. Deregulated expression of MYC
overrides this control, providing a mechanistic model why tumor
cells with high MYC levels depend on NUAK1.
RESULTS
NUAK1 Binds to Chromatin and Interacts with a Nuclear
PP1 Network
Previous studies have shown that NUAK1 associates with PP1
complexes and have identified the cytoplasmic PP1 regulatory
subunit MYPT1 as a major interaction partner of NUAK1 (Zago´r-
ska et al., 2010). Surprisingly, however, endogenous NUAK1
localized mainly to the nucleus of U2OS osteosarcoma cells;(E) Mass spectrometry (MS) analysis of FLAG-NUAK1 co-immunoprecipitates (I
FLAG-tagged NUAK1. Proteins are sorted according to log2 fold enrichment over
to number of peptides identified by MS (n = 2).
(F) Venn diagram of NUAK1 interactors and previously documented PP1 interact
(G) List of the 14 PP1 interactors from (F). Nuclear (green) or cytoplasmic (gray) l
(H) List of selected GO terms enriched by analyzing proteins enriched in both NT-
interactors are shown. FDR, false discovery rate; fold enr., fold enrichment.
(I) Proximity ligation assay (PLA) in U2OS cells documenting proximity of SF3B1
DAPI is used as nuclear counterstain.
See also Figure S1.
1324 Molecular Cell 77, 1322–1339, March 19, 2020the staining occurred in a speckled pattern that partly co-local-
ized with the nuclear pool of the protein phosphatase catalytic
subunit beta (PPP1CB) (Figure 1A). NUAK1 was also localized
mainly in the nucleus in a panel of additional cell lines that we
analyzed (Figure S1A), consistent with a recent study (Palma
et al., 2019). Fractionation experiments showed that a significant
fraction of both NUAK1 and PPP1CB was bound to chromatin
(Figure 1B). To exclude that this staining reflected a cross-reac-
tivity of the antibody, we stably expressed HA-tagged NUAK1
in U2OS and MCF10A cells (HA-NUAK1). Like its endogenous
counterpart, the bulk of HA-NUAK1 localized to the cell nucleus
and bound to chromatin (Figures 1C, 1D, and S1B). Staining of
control cells infected with empty vectors confirmed the speci-
ficity of staining (Figure S1B). Parallel immunostaining confirmed
that MYPT1 is localized mainly in the cytoplasm of U2OS cells
(Figure 1C).
To identify nuclear interaction partners of NUAK1, we immu-
noprecipitated cell lysates of U2OS cells stably expressing
either N-terminally or C-terminally FLAG-tagged NUAK1 with
antibodies directed against the FLAG tag. Control immunopre-
cipitations showed that both amino-terminally and C-terminally
tagged NUAK1 efficiently co-precipitated MYPT1 as well as
PPP1CB (Figure S1C). Mass spectrometry of recovered com-
plexes revealed that immunoprecipitations using an anti-FLAG
antibody from either cell line enriched for a virtually identical
set of proteins relative to control immunoprecipitations from
empty vector-infected cells (Figure 1E). Gene Ontology (GO)
term analyses and comparison with a protein interaction data-
base showed that the immunoprecipitates were significantly
enriched for protein phosphatase complexes and contained
multiple known interactors of PP1, themajority of which localizes
to the nucleus (Figures 1F–1H and S1D). In addition, NUAK1
associated with multiple proteins involved in mRNA splicing
(Figure S1D). Specifically, components of the U2 and U12
spliceosomal small nuclear ribonucleoprotein particle (snRNP)
complexes, which mediate the recognition of the splicing
branching point on pre-mRNA, as well as the Prp19 complex
and the methylosome, which are involved in spliceosome as-
sembly, were enriched in the immunoprecipitates (Figure 1H)
(Chanarat et al., 2011; Chuang et al., 2011; David et al., 2011).
Consistently, immunofluorescence showed that the speckled
pattern of NUAK1 co-localized to a significant degree with the
spliceosomal protein SC35 (encoded by SRSF2), a typical nu-
clear speckle marker (Girard et al., 2012) (Figure S1E), and
proximity ligation assay (PLA) showed that NUAK1 interacts
with SF3B1 (Figure 1I). We have recently characterized the
RNAPII and MYC interactomes, both of which contain multiple
proteins involved in transcription and RNA processing (BaluapuriP) from U2OS cells expressing amino-(NT-IP)- or carboxy-(CT-IP)-terminally-
IP performed in U2OS cells expressing empty vector (EV). Dot size is according
ion partners (BioGrid database).
ocalization is shown.
and CT-IP (n = 154). Terms referring to nuclear protein, splicing factors, or PP1
and NUAK1 or PNUTS. Red dots indicate proximity of the indicated proteins.
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Figure 2. PNUTS Interacts with and Is Phosphorylated by NUAK1 in the Nucleus
(A) Immunoblot of a-HA immunoprecipitates of U2OS cells expressing HA-tagged NUAK1 or empty vector (EV). Input corresponds to 1% lysate (n = 3).
(B) Proximity ligation assay (PLA) performed in U2OS cells expressing HA-tagged NUAK1 or EV (used as negative control). Red dots indicate proximity of the
indicated proteins. DAPI is used as nuclear counterstain (n = 3).
(C) Cartoon depicting the mode of interaction of NUAK1 with MYPT1 and the suggested mode of interaction with PNUTS. Binding motifs of NUAK1 (GILK) and
MYPT1/PNUTS (RVxF) to PP1 are also depicted. Yellow circle, phosphorylation.
(D) PLA performed in U2OS cells expressing HA-tagged NUAK1 or EV (used as negative control). Cells were treated for 3 h with 50 mM GILK or control peptide.
Red dots indicate proximity of the indicated proteins. DAPI is used as nuclear counterstain (n = 3).
(legend continued on next page)
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et al., 2019). The overlap of the NUAK1 interactome with either
the RNAPII or MYC interactome was limited to a small number
of proteins (Figure S1F). Notably, a nuclear PP1 regulatory sub-
unit, PNUTS, that was previously found to interact with RNAPII
(Ciurciu et al., 2013), was also found in the NUAK1 interactome
(see below) and interacted with SF3B1 in PLA assays (Figure 1I).
We therefore explored further the interaction of NUAK1 with nu-
clear PP1 complexes.
PNUTS Interacts with and Is Phosphorylated by NUAK1
in the Nucleus
In the cytoplasm, NUAK1 controls the function of PP1 holoen-
zymes by phosphorylating the MYPT1 regulatory subunit,
thereby altering its function and localization (Zago´rska et al.,
2010). In the nucleus, the catalytic subunit of PP1 interacts
with one of three major subunits: Repo-Man (encoded by the
CDCA2 gene), PNUTS (PP1-nuclear targeting subunit, encoded
by PPP1R10), and NIPP1 (nuclear inhibitor of PP1, encoded by
PPP1R8) (Verheyen et al., 2015). Of those, PNUTS, but neither
Repo-Man nor NIPP1, was present in NUAK1 interactome (Fig-
ures 1G and S1D). This was confirmed by co-immunoprecipita-
tion of PNUTS and HA-NUAK1 (Figure 2A). PLAs showed that
NUAK1 and PNUTS interacted in the nucleus, whereas
NUAK1 and MYPT1 interacted mainly in the cytoplasm (Figures
2B and S2A). Like NUAK1 and PPP1CB, the bulk of PNUTS was
bound to chromatin (Figures 1B and 1D), and like NUAK1,
PNUTS interacted with SF3B1 in PLA assays (Figure 1I).
NUAK1 interacts directly with the catalytic subunit of PP1 holo-
enzymes via a conserved four amino acid motif (GILK) (Zago´r-
ska et al., 2010) (Figure 2C). Consistently, incubation of cells
with a corresponding peptide abolished the interaction of
NUAK1 with both PPP1CB and PNUTS, as documented by
PLAs (Figure 2D). Intriguingly, a phosphoproteomic analysis of
NUAK1-depleted cells (see below) showed that serine 313 of
PNUTS is a potential target site of NUAK1. To confirm this hy-
pothesis, we raised a phospho-specific antibody against this
site. Immunoblots of lysates of transfected cells confirmed
that the antibody recognizes wild-type PNUTS, but neither
S313A, S313D, nor S313E mutant PNUTS expressed at equal
levels (Figure 2E). Depletion of NUAK1 using three different
short hairpin RNAs (shRNAs) (Figure 2F) or a small interfering
RNA (siRNA) (Figure S2B) decreased phosphorylation of
endogenous PNUTS at S313 but had no effect on total PNUTS
levels. We concluded that NUAK1 interacts with nuclear
PNUTS/PPP1CB complexes and phosphorylates PNUTS
on S313.(E) Immunoblot using the indicated antibodies of U2OS cells transfected with pcDN
EVwas used as negative control. In the a-pS313-PNUTS panel, the upper band rep
was used as loading control (n = 3).
(F) U2OS cells were infected with three independent doxycycline (DOX)-inducible
24 h. Asterisk denotes unspecific band (n = 3). Bottom: immunoblot of NUAK1 c
(G) Volcano plot showing differentially regulated phosphosites and the function
analysis upon transfection of a siRNA pool targeting NUAK1 mRNA (siNUAK1). S
(H) Waterfall plot showing differentially spike-in SILAC-labeled phosphorylated
teracting proteins (n = 3).
(I) Differentially phosphorylated residues upon NUAK1 depletion (n = 197, p < 0.05)
function). FDR, false discovery rate; fold enr., fold enrichment.
See also Figure S2.
1326 Molecular Cell 77, 1322–1339, March 19, 2020Regulatory subunits such as PNUTS can either target PP1 cat-
alytic subunits to specific sites or inhibit PP1 activity at specific
subcellular localizations (Verbinnen et al., 2017). To determine
how NUAK1 affects PP1 activity, we performed phosphoproteo-
mic analyses of NUAK1-depleted U2OS cells. The analysis
showed that siRNA-mediated depletion of NUAK1 altered the
phosphorylation of a large set of nuclear proteins (Figure 2G).
Specifically, depletion of NUAK1 downregulated phosphoryla-
tion of many proteins that interact with PP1, suggesting that
NUAK1 inhibits their dephosphorylation (Figure 2H). A GO term
analysis showed that differentially phosphorylated proteins are
broadly involved in RNA processing (Figure 2I). In line with the
function of proteins identified in the NUAK1 interactome, a sub-
set of differentially phosphorylated proteins is involved in RNA
processing and splicing; this includes, for example, SRRM2, a
protein identified as a strong NUAK1 interactor (Figure S1D).
Finally, depletion of NUAK1 also altered the phosphorylation of
multiple proteins not found in the PP1 interactome, arguing
that NUAK1 also has PP1-independent effects and that some
changes in the phosphoproteome are indirect. We concluded
that NUAK1 associates with nuclear PP1 holoenzymes and
the spliceosome and is required for phosphorylation of multiple
proteins involved in RNA processing.
PNUTS Binds Chromatin via RNA and Promotes
Spliceosome Activity
To better understand how PNUTS, PPP1CB, and NUAK1
interact with chromatin, we performed fractionation experiments
upon treatment of nuclear extracts with RNase A, which discrim-
inates resident chromatin proteins from proteins that interact
with chromatin indirectly via RNA. As expected, treatment with
RNase A released a significant fraction of the splicing factor
SF3B1 and the spliceosome-associated NIPP1 protein from
chromatin, while actively transcribing (phosphorylated)
RNAPII or histone H2B remained bound to chromatin (Figures
3A and S3A). Intriguingly, RNase A released a significant fraction
of PNUTS and PPP1CB from chromatin, arguing that both pro-
teins are bound to chromatin at least in part via association
with RNA (Figures 3A and S3A). In contrast, RNase A treatment
did not affect chromatin association of NUAK1 (Figures 3A
and S3A).
The dependence of chromatin association of PNUTS on RNA
is consistent with the presence of an RNA-binding domain in
PNUTS and with previous observations that long noncoding
RNA (lncRNA) molecules can target PNUTS to specific genes
and that PNUTS binds nascent RNA (Bao et al., 2018; KimA3 vectors encoding HA-tagged rat wild-type or S313A/D/E-mutated PNUTS;
resents endogenous PNUTS, while the lower is the exogenous rat protein. VCL
shRNAs targeting NUAK1 and, where indicated, treated with DOX (1 mg/mL) for
onfirming its depletion. VCL was used as loading control (n = 3).
al annotation of respective proteins in a spike-in SILAC phosphoproteomic
ignificance is indicated by the dashed line (p < 0.05) (n = 3).
residues (p < 0.05) upon NUAK1 depletion. Orange, phosphosites of PP1-in-
were used as input for a GO term analysis (left: cell component; right: biological
A B
E F G
C
D
Figure 3. PNUTS Binds Chromatin via RNA and Promotes Spliceosome Activity
(A) Immunoblot documenting chromatin association of the indicated proteins in control cell lysates and in lysates upon RNase A treatment. Cell fractionation was
performed on U2OS cells expressing HA-tagged NUAK1. Nucleopl., nucleoplasmic fraction; chromatin, chromatin-bound fraction. SF3B1 and NIPP1 or
phosphorylated RNAPII and H2B were used as RNA- and chromatin-bound controls, respectively (n = 3).
(B) Expression of PNUTS-bound genes (n = 2,786) versus all expressed genes (n = 19,382). The p value was calculated with a two-tailed Wilcoxon rank-sum test.
CPM, counts per million.
(legend continued on next page)
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et al., 2003; Xing et al., 2014). To determine the sites on chro-
matin to which PNUTS is bound in an unbiased manner, we
performed chromatin immunoprecipitation followed by
sequencing (ChIP-seq). A correlation of ChIP-seq data with
RNA sequencing (RNA-seq) data showed that PNUTS-bound
genes display relatively high levels of expression but did not
reveal a significant enrichment of specific functional categories
of PNUTS-bound genes (Figure 3B). Importantly, ChIP-seq
showed that PNUTS bound both downstream of the tran-
scription start site (TSS) of 2,571 genes and close to the tran-
scription end site (TES) at 584 genes, as demonstrated both
by inspection of multiple individual genes and global analyses
(Figures 3C–3E). PNUTS binding downstream of the TSS peaked
around the RNAPII pause site and both immediately 50 and 30 of
the first exon-intron boundary (Figure 3D). Previous observations
have implicated PNUTS in transcription termination (Austenaa
et al., 2015; Cortazar et al., 2019). Consistently, a major PNUTS
peak was observed around the TES (Figures 3C and 3E). Our
analysis also confirmed previous observations that PNUTS
avidly binds histone clusters (Figure S3B) (Verheyen et al.,
2015). ChIP-seq with exogenous reference genome spike-in
(ChIP-RX) using the phospho-specific antibody showed that
chromatin association of phosphorylated pS313-PNUTS
closely resembled that of total PNUTS (Figures 3C–3E). ChIP ex-
periments upon RNase A confirmed that PNUTS bound to
both promoter-proximal and TES in part via interaction with
RNA (Figure 3F). Consistent with the observation that PNUTS
is part of the interactome of newly transcribed RNA (Bao et al.,
2018), treatment of cells with flavopiridol (FP), an inhibitor of
the CDK9 kinase that globally blocks nascent RNA synthesis,
attenuated PNUTS chromatin binding (Figures 3D and S3C).
We concluded that PNUTS binds chromatin in part via associa-
tion with nascent RNA.
The localization of PNUTS binding, its dependency on RNA,
and the co-precipitation of PNUTS with spliceosomal proteins
suggested that PNUTS has a role in splicing. Indeed, PP1 activity
affects the phosphorylation status of several splicing factors,
thereby regulating both spliceosome assembly and its catalytic
cycle (Aubol et al., 2017; Shi et al., 2006). To test this hypothesis,
we used two phospho-specific antibodies that recognize
phosphorylated T313 and T328 in the TP-rich domain of
SF3B1 (Figure S3E); these residues are phosphorylated exclu-
sively in catalytically active spliceosomes (Girard et al., 2012).
Indeed, the U2 spliceosome component SF3B1 is a well-
described PP1 target, which is hyperphosphorylated during the
first step of catalysis and dephosphorylated during the second
one (Girard et al., 2012; Shi et al., 2006; Tanuma et al., 2008).(C) Genome Browser tracks showing PNUTS, phospho-S313-PNUTS (pPNUTS
control.
(D) Average density plots of PNUTS ChIP-seq (left y axis) and pPNUTS ChIP-R
start site.
(E) Average density plots of PNUTS ChIP-seq (left y axis) and pPNUTS ChIP-RX (r
indicates SEM.
(F) PNUTS ChIP performed upon RNase A treatment. IgG ChIP was used as antib
neg ct, negative control (mean ± SD of technical triplicates of a representative e
(G) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites. U
treated with 25 nM calyculin A for 30 min. ACTB was used as loading control (n
See also Figure S3.
1328 Molecular Cell 77, 1322–1339, March 19, 2020Depletion of PNUTS strongly reduced phosphorylation at both
sites and inhibition of PP1 using the phosphatase inhibitors
calyculin A and okadaic acid (which target both PP1 and PP2A
phosphatases) reverted the inhibition (Figures 3G and S3D).
Collectively, the data indicate that PNUTS locally inhibits PP1
downstream of the TSS of actively transcribed genes to promote
spliceosome activity.
NUAK1 Controls Chromatin Association of PNUTS
To understand whether NUAK1 affects PNUTS function, we
incubated U2OS cells with the GILK peptide that blocks
NUAK1 interaction with PP1 and found that this led to a strong
decrease in SF3B1 phosphorylation (Figure 4A), indicating that
NUAK1 or a structurally related kinase is required for spliceo-
some activity. Consistently, both shRNA- and siRNA-mediated
depletion of NUAK1 reduced SF3B1 phosphorylation at T313
and T328, although the effects were not as strong as with the
GILK peptide (Figures 4B and 4C). We reasoned that this might
be due to the relatively slow kinetics of a depletion experiment,
whichmight allow cells to adapt to a decrease in NUAK1 activity.
To test this hypothesis, we used two chemically distinct small
molecules to acutely inhibit NUAK1. The first is BAY-880, which
we identified as a potent inhibitor of NUAK1 that inhibits 96% of
its kinase activity at 1 mM concentration (Figures S4A and S4B;
Table S1). Testing BAY-880 against a panel of 274 kinases
showed that NUAK1 is the best target and identified a small
number of additional kinases that may be inhibited by this
compound (Figure S4B; Table S1). Consistent with this, a phos-
phoproteomic analysis showed that the changes in phosphory-
lation induced by siRNA-mediated depletion of NUAK1 in
U2OS cells showed a statistically highly significant overlap with
changes induced by BAY-880 (Figure 4D; p = 1.5 3 1013),
and a GO term analysis of changes of differentially regulated
phosphosites showed that processes targeted by BAY-880
highly overlapped with the ones targeted by depletion of
NUAK1 (Figure 4D). Importantly, both depletion of NUAK1 and
BAY-880 jointly targeted multiple proteins involved in RNA
metabolism and, specifically, RNA splicing, 30 end processing,
and localization (Figures 4D and S4C). In addition, we used a
well-characterized NUAK1 inhibitor, HTH-01-015 (Banerjee
et al., 2014a). Notably, potential off-target activities of BAY-
880 greatly differed from those of HTH-01-015, arguing that
joint targets of both inhibitors reflect on-target effects resulting
from NUAK1 inhibition (Figure S4B). We therefore confirmed
that both compounds decrease phosphorylation of S313-
PNUTS and observed that BAY-880 was more potent than
HTH-01-015 in inhibiting NUAK1 activity (Figures 4E and S4D).), and RNAPII binding to representative genes. Input tracks are included as
X (right y axis). The shadow around tracks indicates SEM. TSS, transcription
ight y axis) centered to transcription end site (TES). The shadow around tracks
ody specificity control. TSS, transcription start site; 30RT, 30 readthrough site;
xperiment; n = 3).
2OS cells were transfected with a siRNA pool targeting PNUTS and, 48 h later,
= 3).
A B C
ED
F G
H I
(legend on next page)
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Phosphoproteomic analyses showed that acute inhibition by
either inhibitor targeted highly overlapping sets of RNA-process-
ing proteins, as observed in response to depletion of NUAK1
(Figures S4E–S4G; compare with Figure S4C). A potentially rele-
vant off-target activity of BAY-880 is inhibition of CDK9; also,
PNUTS has been implicated in the phosphorylation of the CTD
of RNAPII at serine 5 (Ciurciu et al., 2013). However, both BAY-
880 andHTH-01-015 had onlyminor effects on S2- or S5-RNAPII
phosphorylation, while the CDK9 inhibitors FP and LDC00067 or
inhibitors of other transcription-associated CDKs essentially
abolished phosphorylation at S2 (Figure S5A). Furthermore,
comparison of the phosphosites identified by phosphoproteo-
mics upon BAY-880 or siRNA-mediated depletion of NUAK1
with recently described CDK9 targets (Sanso´ et al., 2016)
showed only a statistically nonsignificant overlap (Figure S5B).
We concluded that the effects of both drugs are not mediated
via inhibition of CDK9 and that NUAK1 has no direct role in
RNAPII phosphorylation. Both NUAK1 inhibitors reduced phos-
phorylation of SF3B1 at the sites that indicate spliceosome
activity; the decrease in phosphorylation was stronger in
response to BAY-880, correlating with the stronger inhibition of
NUAK1-dependent phosphorylation of S313-PNUTS (Figure 4E).
PNUTS ChIP-seq and pS313-PNUTS ChIP-RX showed that
chromatin association both at TSS and TES was strongly
reduced by inhibition of NUAK1 (Figures 4F, 4G, and S5C). Com-
parison of chromatin binding of wild-type PNUTS with S313A-
mutated PNUTS showed that this decrease was due partly to
the decreased phosphorylation at this site, but the magnitude
in the decrease observed after NUAK1 inhibition revealed that
other events (e.g., changes in spliceosomal proteins) contribute
to the decrease in association (Figure 4H). In contrast, S313A-
PNUTS showed no difference to wild-type PNUTS in terms of
binding to PP1 and nuclear localization (not shown). Finally,
BAY-880 effect on splicing activity was compared with that of
pladienolide B (PlaB), a well-characterized splicing inhibitor
(Kaida et al., 2007; Kotake et al., 2007). PlaB abolished SF3B1
phosphorylation, while BAY-880 inhibited SF3B1 phosphoryla-Figure 4. NUAK1 Controls Chromatin Association of PNUTS
(A) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites. U2
used as loading control (n = 3).
(B) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites.
NUAK1 mRNA (shNUAK1 #3 in Figure 2F) was induced with DOX for 24 h. ACTB
(C) Same as B, but using and siRNA pool targeting NUAK1 (siNUAK1) or control
(D) Left: Venn diagram showing the overlap between significantly differentially regu
(48 h) or treatment with 10 mMBAY-880 (2 h) in a TMT phosphoproteomic experim
is a Venn diagram showing the overlap between all identified GO terms; below is
(E) Immunoblots documenting phosphorylation of PNUTS at S313 and of SF3B1
concentrations of BAY-880 or HTH-01-015. ACTB was used as loading control (
(F) Read density plot analysis of PNUTS ChIP-seq upon 4 h 10 mM BAY-880 trea
SEM. TSS, transcription start site; TES, transcription end site.
(G) Genome Browser track at the TPM1 gene of PNUTS ChIP-seq and phospho-S
880. Input tracks are included as control.
(H) ChIP experiments using an a-HA antibody showing chromatin association o
expression plasmids encoding HA-tagged PNUTS or empty vector (EV). IgG ChIP
readthrough site; neg ct, negative control (mean ± SD of technical triplicates of a
(I) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites afte
4 h. VCL was used as loading control. Quantification of T313- and T328-SF3B1 ba
intensity from three independent experiments.
See also Figures S4 and S5 and Table S1.
1330 Molecular Cell 77, 1322–1339, March 19, 2020tion by 50%–70%. (Figures 4I and S5D). Notably, PlaB did not
affect S313-PNUTS phosphorylation, confirming that PlaB activ-
ity on SF3B1 is PNUTS-independent (Figure S5D) (Kotake et al.,
2007). Interestingly, dephosphorylation of S313 upon NUAK1 in-
hibition by either BAY-880 or HTH 01-015 was essentially com-
plete within 1 h treatment (Figure S5D), suggesting that the ef-
fects of the inhibitors on PNUTS or SF3B1 phosphorylation are
direct. We concluded that phosphorylation by NUAK1 promotes
chromatin association of PNUTS and spliceosome activity.
NUAK1 Promotes Splicing and Transcription
Termination
To determine whether NUAK1 is required for co-transcriptional
splicing, we labeled nascent RNA using a pulse of 15 min with
4-thiouridine (4sU) and sequenced labeled RNA either immedi-
ately (pulse) or 2 h after 4sU withdrawal (chase; Figure S5E).
The experiment was performed in control (DMSO) cells as well
as in the presence of BAY-880 or PlaB. As expected, the per-
centage of exonic and spliced reads strongly increased during
the chase, reflecting processing of pre-mRNA (Figure 5A). PlaB
blocked the increase in exonic and spliced reads and caused a
marked increase in intronic reads, indicating that PlaB blocked
splicing (Figure 5A). Similarly, inhibition of NUAK1 impaired the
increase in spliced and exonic reads, although the effect was
weaker than for PlaB (Figure 5A). Inspection of individual genes
confirmed this observation (Figure 5B). Plotting the number of
spliced reads per gene confirmed that the number of reads per
gene increased during the chase in control (DMSO) cells but re-
mained constant in BAY-880-treated cells and slightly
decreased in PlaB-treated cells (Figure 5C).
The weaker effect of BAY-880 on overall splicing relative to
that of PlaB is consistent with the lesser extent of BAY-880-
mediated SF3B1 dephosphorylation (Figures 4I and S5D). We
reasoned that the role of NUAK1 might be restricted to a subset
of genes, compared with the genome-wide effect of PlaB. We
therefore performed a ranked sum gene set enrichment analysis
(GSEA) (Subramanian et al., 2005), ranking genes on the basis ofOS cells were treated 4 h with 50 mMGILK (or control [CT]) peptide. ACTB was
U2OS cells stably expressing a doxycycline (DOX)-inducible shRNA targeting
was used as loading control (n = 3).
siRNA pool. ACTB was used as loading control (n = 3).
lated phosphosites identified in response to siRNA-mediatedNUAK1 depletion
ent. Right: GO term analysis of differentially phosphorylated proteins. At the top
a pie chart of categories of 48 RNA-related GO terms.
at the indicated sites after 24 h incubation of U2OS cells with the indicated
n = 3).
tment (n = 3,172 PNUTS-bound genes). The shadow around tracks indicates
313-PNUTS (pPNUTS) ChIP-RX from U2OS cells treated 4 h with 10 mMBAY-
f wild-type PNUTS and of PNUTS S313A after transfection in U2OS cells of
was used as antibody specificity control. TSS, transcription start site; 30RT, 30
representative experiment; n = 3).
r treatment of U2OS cells with 10 mMBAY-880 or 1 mMpladienolide B (PlaB) for
nds was compared with DMSO-treated samples and normalized to VCL band
A B
C
D
E F
Figure 5. NUAK1 Promotes Splicing and Transcription Termination
(A) Left: definition of read categories; orange reads represent mature mRNA, yellow reads pre-mRNA. Right: percentage (average ± SD) of reads identified in the
nascent RNA-seq analysis described in Figure S5F.
(B) Genome Browser tracks of 4sU-labeled RNA recovered from a pulse-chase experiment performed as described in Figure S5F. For each chased (C) sample,
three replicates (rep) are reported. Tracks were first normalized to overall reads, then exonic reads were electronically removed.
(C) Kernel density plot of the number of reads harboring splice junctions (spliced reads; see A). Read counts were normalized to the number of exons per gene and
the bandwidth was set to 0.3. Genes without spliced reads were removed. The mean over all replicates was plotted (DMSO, n = 16,257; BAY-880, n = 14,602;
PlaB, n = 13,216; DMSO pulse, n = 13,249).
(D) Gene sets identified by a GSEA on GO terms of genes showing splicing defects upon NUAK1 inhibition. Genes were ranked according to their splicing score.
Splicing score was defined as the ratio between reads harboring splice junctions (spliced reads; see A) and pre-mRNA reads (reads falling into introns and intron-
exon-spanning reads; yellow in A).
(legend continued on next page)
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a ‘‘splicing score’’ (defined as the ratio between spliced reads
and pre-mRNA reads). Intriguingly, this analysis showed that
the gene sets most strongly affected by NUAK1 inhibition were
enriched for genes encoding proteins of the basic transcription
machinery and nuclear structure (Figure 5D). Inspection of indi-
vidual genes in the top enriched gene sets illustrated the strong
effect of NUAK1 inhibition on intron retention of these mRNAs
(Figure S5F). The data suggest that expression of genes of the
core transcriptional machinery is particularly sensitive to defects
in NUAK1 activity.
Incubation of cells with BAY-880, but not with PlaB, also led to
a strong increase in intergenic reads (Figure 5A). As described
before, PNUTS also controls transcription termination (Austenaa
et al., 2015; Cortazar et al., 2019). Consistent with these obser-
vations, BAY-880 induced a marked increase of 30 readthrough
reads (TES-RT; positioned 30 of the TES), representing inaccu-
rately terminated transcripts (Figures 5E and 5F). We concluded
that NUAK1 promotes both termination genome-wide and
splicing of a specific subset of genes encoding proteins of the
transcription machinery.
NUAK1 Controls a MYC-Sensitive Feedback Control of
Transcriptional Elongation
To understand whether the role of NUAK1 in splicing affects
transcription, we performed both RNAPII ChIP-RX and 4sU
pulse labeling of nascent RNA. In control cells, NUAK1 inhibition
had no significant effect on RNAPII association with the TSS,
the pause site, or the first exon-intron boundary (Figures 6A
and 6B). In contrast, NUAK1 inhibition decreased overall
RNAPII occupancy at the TES, suggesting that transcription
elongation is impaired on many genes (Figure 6C). Consistent
with this interpretation, we noted that overall nascent RNA
synthesis, as tested by pulse labeling with 4sU, was significantly
reduced upon NUAK1 inhibition (Figures 7A and 7B).
To understandwhether elevated levels of MYC influence these
effects, we performed 4sU labeling and RNAPII ChIP-RX exper-
iments on samples treated with BAY-880 16 h after the activation
of a MYC-ER chimera. We first validated that induction of MYC
did not alleviate the dependence of SF3B1 phosphorylation on
NUAK1 (Figure S6A), indicating that it did not alter the depen-
dence of spliceosome activity on NUAK1. Analysis of nascent
RNA synthesis by a pulse of 4sU showed that activation of
MYC strongly enhanced nascent RNA synthesis (Figures 7A,
7B, and S6B). In addition, activation of MYC strongly attenuated
the decrease in nascent RNA synthesis caused by inhibition of
NUAK1 on multiple genes (Figure 7A). Global analyses showed
that MYC increased nascent RNA synthesis throughout the
gene body in control cells; in contrast, the MYC-dependent in-
crease was confined to promoter-proximal regions in the pres-
ence of BAY-880 (Figure 7B). Activation of MYC did not atten-
uate or override the block in transcription elongation caused(E) Top: kernel density plot of the termination score. The mean over all replicates w
18,907; PlaB, n = 17,639; DMSO pulse, n = 16,342). Bottom: definition of terminati
reads are defined as all reads falling into introns and intron-exon-spanning reads
(F) Genome Browser tracks of nascent RNA expression of a representative gene
(cumulative gene browser picture from three independent replicates).
See also Figure S5.
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that MYC specifically overrides the inhibition of nascent RNA
synthesis caused by BAY-880 (Figures 7B and S6C). Remark-
ably and consistent with the 4sU data, RNAPII globally accumu-
lated downstream of the TSS upon NUAK1 inhibition in cells with
high levels of MYC (Figures 6A and 6B). Specifically, RNAPII
accumulated at the pause site and both 50 and 30 of the first
exon-intron boundary (Figure 6B). This localization closely paral-
leled the chromatin association of PNUTS (compare Figure 3D
with Figure 6B; Figure S6D). Comparison with published data
describing the changes in RNAPII chromatin association in
response to CDK9 inhibition (Olson et al., 2018) showed that
although inhibition of CDK9 causes an accumulation of RNAPII
at the pause site, the peaks 50 and 30 of the first exon-intron
boundary were observed only in response to inhibition of
NUAK1 (Figure S6E). We suggest that this accumulation reflects
a delay or block in transcription elongation in response to a
defect in mRNA splicing caused by inhibition of NUAK1.
Notably, RNA-seq showed that the accumulation of RNAPII
upon NUAK1 inhibition in cells with high MYC levels was not
paralleled by an increase in mRNA synthesis, arguing that
the accumulating RNAPII is non-productive (Figure S7A).
Consistently, RNAPII ChIP-RX showed that NUAK1 inhibition
strongly suppressed RNAPII occupancy at the TES also in
cells with active MYC (Figure 6C). Taken together, we
concluded that inhibition of spliceosome assembly exerts a
negative control on pause release or early steps of transcription
elongation, which is overridden by elevated levels of MYC,
leading to the accumulation of RNAPII at the first exon-intron
boundary. The 4sU pulse-chase experiment also showed that
inhibition of NUAK1 caused a striking increase in TES-RT/inter-
genic reads in both control and high-MYC cells, both on a global
scale and when inspecting individual genes, consistent with
the role of NUAK1 and PNUTs in termination (Figures S7B
and S7C).
To understand how inhibition of NUAK1 exerts the effects on
early elongation, we reasoned that splicing defects can lead to
the accumulation of stable hybrids of nascent RNA with DNA,
termed R-loops (Chen et al., 2018). To analyze this, we initially
chose two genes that require NUAK1 for splicing, ACTB and
NCL (Figures 7C and S7D). Comparison with a recently pub-
lished genome-wide sequencing dataset obtained from U2OS
cells showed that R-loops are widespread over both genes
(De Magis et al., 2019). Immunoprecipitations using a mono-
clonal antibody (S9.6) that specifically recognizes DNA-RNA
hybrids showed that inhibition of NUAK1 caused R-loop accu-
mulation at both ACTB and NCL gene loci (Figure 7D) and at
multiple other genes bearing R-loops, as shown in the
genome-wide analysis (Figures 7D and S7E). Incubation of
chromatin with RNase H, which selectively degrades DNA-
RNA hybrids, removed the signal, confirming its specificityas plotted and the bandwidth was set to 0.3 (DMSO, n = 18,782; BAY-880, n =
on score as reads in TES or TES + 20 kb/pre-mRNA reads, whereas pre-mRNA
(i.e., yellow in A).
displaying termination readthrough. Tracks were generated as described in B
AB
C
Figure 6. NUAK1 Controls RNAPII-Mediated Elongation in a MYC-Dependent Manner
(A) RNAPII occupancy at three representative genes. Blue, Genome Browser tracks of RNAPII ChIP-RX upon treatment with 4 h 10 mM BAY-880 or DMSO in
control cells ( MYC) or upon 20 h MYC-ER activation with 100 nM 4-OHT (+ MYC). Red, read difference between BAY-880 and DMSO samples.
(B) Read density plots of RNAPII ChIP-RX analysis upon treatment with 4 h 10 mMBAY-880 or DMSO in control cells (MYC) or upon 20 hMYC-ER activationwith
100 nM 4-OHT (+ MYC). Plots are centered to transcription start site (TSS, left), RNAPII pause site (middle), or first exon-intron boundary (right).
(C) Read density plots of RNAPII ChIP-RX analysis upon treatment with 4 h 10 mMBAY-880 or DMSO in control cells (MYC) or uponMYC-ER activation (+MYC).
Plots are centered to transcription end site (TES). The shadow around tracks indicates SEM.
See also Figure S6.(Figures 7D and S7E). In neuroblastoma cells, R-loop accumula-
tion correlates with stalling of RNAPII and with recruitment of
mRNAde-capping enzymes, which trigger transcription termina-
tion (Brannan et al., 2012; Herold et al., 2019). Consistent with
these observations, NUAK1 inhibition led to recruitment of
DCP1A, a core subunit of mRNA de-capping complexes, to
several promoter-proximal regions that we tested (Figure 7E).Elevated MYC levels attenuated both R-loop accumulation and
the recruitment of mRNA de-capping factors in response to
NUAK1 inhibition (Figures 7D, 7E, and S7E). We concluded
that inhibition of NUAK1 and spliceosome activity induces
R-loop accumulation and recruitment of mRNA de-capping fac-
tors and that MYC overrides this feedback-like control, indi-
cating a model in which MYC drives transcriptional elongationMolecular Cell 77, 1322–1339, March 19, 2020 1333
A B
C D
E F
Figure 7. NUAK1 Affects Nascent RNA Synthesis, R-Loop Formation, and De-capping enzyme Recruitment in a MYC-Dependent Manner
(A) Nascent RNA synthesis of two representative genes as determined by a 15 min pulse of 4sU incorporation (P). Blue, Genome Browser tracks of nascent RNA
upon treatment with 4 h 10 mM BAY-880 or DMSO in control cells ( MYC) or upon MYC-ER activation (+ MYC; 20 h). Flowchart of experiment is shown in
Figure S5E. Tracks were generated as described in Figure 5B. Gray, ratio of reads in DMSO and BAY-880-treated samples.
(legend continued on next page)
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in the absence of correctly assembled spliceosomes upon
NUAK1 inhibition (Figure 7F).
DISCUSSION
Previous work has established that NUAK1 takes part in a
trimeric complex with the catalytic subunit of PP1 and phos-
phorylates a regulatory subunit, MYPT1, in the cytoplasm (Za-
go´rska et al., 2010). Here, we extend this model by showing
that a large fraction of NUAK1 is localized in the cell nucleus, as-
sociates with nuclear PP1 holoenzymes, and phosphorylates
one of the major nuclear targeting subunits of PP1, PNUTS, at
S313. Consistent with previous work that has implicated
dephosphorylation by PP1 in controlling spliceosome activity,
NUAK1 associates with spliceosomes (Girard et al., 2012; Shi
et al., 2006; Tanuma et al., 2008). Both PNUTS and NUAK1
are required for spliceosome activity and splicing of large sets
of mRNAs. From these data, we propose a model in which
PNUTS localizes to chromatin via its interaction with nascent
RNA. As consequence, PNUTS comes into contact with chro-
matin-bound NUAK1, and its association with nascent RNA is
stabilized by NUAK1-dependent phosphorylation. The stabiliza-
tion locally inhibits PP1 activity toward spliceosomal proteins
and enables spliceosome activation (Figure 7F). Inhibition of
NUAK1 does not only impair spliceosome activity but also glob-
ally reduces nascent RNA synthesis and induces recruitment of
mRNA de-capping factors. This suggests that regulation of PP1
activity also plays a critical role in coordinating transcription
elongation with spliceosome activity. Previous observations
have shown that elongating RNAPII associates with spliceo-
somes and accumulates over intron regions when spliceosome
activity is perturbed (Chathoth et al., 2014; Nojima et al., 2018).
Furthermore, the spliceosomal U1 RNP is part of a control
mechanism that links pausing of RNAPII at the first stable nucle-
osome to premature polyadenylation-mediated termination
(Chiu et al., 2018). Loss of PNUTS enhances phosphorylation
of RNAPII at S5 in Drosophila embryos (Ciurciu et al., 2013).
Although this may suggest a direct dephosphorylation of
RNAPII by catalytically active PNUTS/PP1 holoenzymes in
Drosophila, this increase may also be due to stalling of RNAPII
(as seen in high-MYC cells) rather than to a direct role of
PNUTS/PP1 in de-phosphorylating RNAPII. This interpretation(B) Transcription start site (TSS)-centered read density plot (n = 6,133) of 4sU-lab
1 mM flavopiridol (FP), 1 mM NVP-2, or DMSO in control cells ( MYC) or upon M
(C) Top: Genome Browser track of a region of chromosome 7 showing DRIP(DNA
bars, genes. Magnification shows detail of ACTB gene. Bottom: blue, Genome
treatment with 4 h 10 mM BAY-880 or DMSO in control cells ( MYC) or upon 20
BAY-880 and DMSO samples. Red arrows indicate the position of primers used
(D) Left: DRIP-qPCRs of U2OSMYC-ER cells treated with DMSO or 10 mMBAY-8
RNase H treatment and a negative region were used to test antibody specificity. R
ER cells treated as in the left plot. The plot shows average of 38 genetic loci (Figure
normalized to their respective DMSO/-MYC condition. Dots represent values in
performed to compare the different conditions (n.s., not significant).
(E) DCP1A ChIP of U2OS MYC-ER cells treated with DMSO or 10 mM BAY-880 f
tested genetic loci reside at the TSS of the indicated genes. IgG ChIP and a nega
(mean ± SD of technical triplicates of a representative experiment; n = 2).
(F) Model summarizing our findings. For details, see text.
See also Figures S6 and S7.is consistent with the observation that phosphorylation of S5
of RNAPII slows down elongation to promote spliceosome ac-
tivity, whereas dephosphorylation of RNAPII enables rapid
transcription of exonic sequences (Nojima et al., 2015). Our
data argue that the localized inhibition of PP1 is a critical part
of these checkpoint-like processes that link elongation to spli-
ceosome activity.
Previous work has also established that a CDK9/PP1 switch is
critical for transcription termination, and PP1 loss of function
induces termination defects (e.g., readthrough transcription)
(Cortazar et al., 2019; Kecman et al., 2018; Parua et al., 2018).
Consistently, our and previously published (Austenaa et al.,
2015; Cortazar et al., 2019) observations implicate PNUTS in
transcription termination. The data represented here extend
this model to show that NUAK1 also affects the function of
PNUTS in transcription termination.
Previous work both in tissue culture and in vivo has estab-
lished that MYC-driven cells and tumors depend on NUAK1 for
growth (Liu et al., 2012; Monteverde et al., 2018; Port et al.,
2018). We did not observe any effect of NUAK1 depletion or in-
hibition onMYCphosphorylation at S62 and T58 orMYC stability
or an association of NUAK1 with MYC, hence it is unlikely that
the dependence of cells expressing deregulated MYC on
NUAK1 reflects a previously described role of PNUTS in MYC
turnover (Dingar et al., 2018). We show here that activation of
MYC did not remove the requirement for NUAK1 in spliceosome
activity. However, MYC strongly attenuated the reduction in
nascent RNA synthesis, abolished the recruitment of de-capping
complexes, and suppressed accumulation of R-loops upon
NUAK1 inhibition at all loci we tested. Upon NUAK1 inhibition
in cells expressing high MYC levels, RNAPII did not terminate
transcription but accumulated both at the pause site and at the
first exon-intron boundary. Notably, this increase in RNAPII as-
sociation caused by NUAK1 inhibition was not mirrored by a cor-
responding increase in RNA synthesis, arguing that RNAPII
accumulated in a non-productive form. Our data therefore sug-
gest a model in which the perturbed spliceosome function
upon NUAK1 inhibition induces RNAPII to terminate in cells
with physiological MYC levels. In contrast, upon NUAK1 inhibi-
tion in MYC-driven tumor cells termination is suppressed and
RNAPII is trapped in a form that is not involved in productive tran-
scription (Figure 7F).eled nascent RNA (15 min pulse; P) upon 2 h treatment with 10 mM BAY-880,
YC activation (+ MYC; 18 h). The shadow around tracks indicates SEM.
-RNA-immunoprecipitation)-seq data in U2OS cells (GEO: GSE115957). Black
Browser tracks showing RNAPII occupancy at the ACTB gene locus upon
h MYC activation with 100 nM 4-OHT (+ MYC). Red, read difference between
for DRIP-qPCR (D).
80 for 4 h and, where indicated, co-treated with 100 nM 4-OHT for 20 h (MYC).
ight: box blot summarizing all performed DRIP-qPCR analyses of U2OSMYC-
S7I) tested in three biologically independent experiments. All sets of data were
the 10th to 90th percentiles. Wilcoxon matched-pairs signed rank tests were
or 4 h and, where indicated, co-treated with 100 nM 4-OHT for 20 h (MYC). All
tive region were used as antibody specificity controls. Neg ct, negative control
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A strongly enhanced sensitivity of MYC-driven cells to a
perturbation of the splicingmachinery has been observed before
in different biological systems; specifically, upregulation of the
core spliceosome machinery is an essential step in MYC-driven
lymphomagenesis, and MYC-driven lymphomas depend on
PRMT5, an arginine methyltransferase that methylates spliceo-
somal proteins (Koh et al., 2015). Furthermore, genetic or phar-
macological inhibition of the spliceosome in vivo impairs survival
and tumorigenicity of MYC-dependent breast cancers (Hsu
et al., 2015). Finally, activation of MYC renders cells sensitive
to inhibition of the CLK2 kinase, which has been linked to alter-
native splicing (Iwai et al., 2018). Similarly, the extreme sensitivity
of MYC-transformed cells to depletion of glutamine (Dang, 2011)
is linked to the ability ofMYC to drive transcriptional elongation in
the absence of a sufficient nucleotide supply, leading to R-loop
accumulation in the body of highly transcribed genes (Dejure
et al., 2017). The notion that deregulated expression of MYC
strongly sensitizes tumor cells toward a wide range of pro-
apoptotic stimuli is considered a mechanism that protects
from tumorigenesis (Lowe et al., 2004). Although the induction
of individual target genes by MYC, such as BIM1, contributes
to this sensitization (Muthalagu et al., 2014), the aggregate of
available data argues that tumor cells that express elevated
MYC levels ignore checkpoints that restrict early transcription
and that the ensuing trapping of RNAPII is a common mecha-
nism underlying these well-documented vulnerabilities of cells
expressing oncogenic levels of MYC, for example by causing
conflicts with the replication fork during S-phase that lead to
double-strand breaks (Hamperl and Cimprich, 2016).STAR+METHODS
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Mouse monoclonal anti-ACTB Sigma-Aldrich Cat #A5441 RRID:AB_476744 Lot: 026M4780V
Mouse monoclonal anti-VCL Sigma-Aldrich Cat #V9131 RRID:AB_477629 Lot: 036M4797V
Rabbit polyclonal anti-NUAK1 (used for
immunofluorescence)
Sigma-Aldrich Cat# HPA057143 RRID:AB_2683349 Lot: R80360
Mouse monoclonal anti-FLAG M2 Sigma-Aldrich Cat #F3165 RRID:AB_259529 Lot: SLBT6752
Mouse monoclonal anti-HA-tag (used for
immunofluorescence)
Abcam Cat# ab130275 RRID:AB_11156884
Lot: GR320538-5
Rabbit polyclonal anti-HA-tag (used for ChIP) Abcam Cat# ab9110 RRID:AB_307019) Lot: GR3177614-4
Rabbit monoclonal anti-MYC (clone Y69) Abcam Cat# ab32072 RRID:AB_731658 Lot: GR295111-34
Rabbit polyclonal anti-phospho-Ser2-RNAPII Abcam Cat# ab5095 RRID:AB_304749 Lot: GR3231908-1
Rabbit polyclonal anti-TUBA1A Santa Cruz Biotechnology Cat# sc-12462 RRID:AB_2241125
Mouse monoclonal anti-PNUTS (used for
immunoblotting)
Santa Cruz Biotechnology Cat# sc-271681 RRID:AB_10708580 Lot: K1913
Mouse monoclonal anti-PPP1CB Santa Cruz Biotechnology Cat# sc-373782 RRID:AB_10916703
Rabbit monoclonal anti-phospho-Thr313-SF3B1 Cell Signaling Technology Cat# 25009 RRID:AB_2798893 Lot: 1
Rabbit monoclonal anti-HA-tag (used for
immunoblotting)
Cell Signaling Technology Cat# 3724 RRID:AB_1549585 Lot: 7
Rabbit monoclonal anti-MYPT1 Cell Signaling Technology Cat# 8574 RRID:AB_10998518 Lot: 1
Rabbit polyclonal anti-NUAK1 (used for
immunoblotting)
Cell Signaling Technology Cat# 4458 RRID:AB_2155859 Lot: 3
Rabbit polyclonal anti-PNUTS (used for ChIP,
immunofluorescence and immunoblotting)
Bethyl Laboratories Cat# A300-439A RRID:AB_420948 Lot: 439A-3
Mouse monoclonal anti-SF3B1 MBL International Cat# D221-3 RRID:AB_592712
Mouse monoclonal anti-RNAPII MBL International Cat# MABI0601 RRID:AB_2728735
Mouse monoclonal anti-phospho-Ser5-RNAPII BioLegend Cat# 904001 RRID:AB_2565036
Mouse monoclonal anti-RNA-DNA hybrid
(clone S9.6)
Kerafast Cat# ENH001 RRID:AB_2687463
Mouse monoclonal anti-SC35 BD PharMingen Cat# 556363 RRID:AB_396388
Rabbit polyclonal anti-phospho-Thr328-SF3B1 L€uhrmann lab Girard et al., 2012
Rabbit polyclonal anti-phospho-Thr313-SF3B1 L€uhrmann lab Girard et al., 2012
Rabbit polyclonal anti-phospho-Ser313-PNUTS Raised for this study (Davids
Biotechnologie)
N/A
IRDye 800CW Donkey anti-Rabbit IgG (H + L) LI-COR Biosciences Cat# 926-32213 RRID:AB_621848
IRDye 680RD Donkey anti-Mouse IgG (H + L) LI-COR Biosciences Cat# 926-68072 RRID:AB_10953628
Goat anti-Rabbit IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488
Thermo Fisher Scientific Cat# A-11008 RRID:AB_143165
Goat anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 568
Thermo Fisher Scientific Cat# A-11004 RRID:AB_2534072
Bacterial and Virus Strains
pBABE-puro (empty vector) This study N/A
pBABE-Nuak1-FLAG-NT-puro This study N/A
pBABE-Nuak1-FLAG-CT-puro This study N/A
pBABE-Nuak1-HA-NT-puro This study N/A
pBABE-Nuak1-HA-CT-puro This study N/A
pINDUCER11-NUAK1#1 This study N/A
(Continued on next page)
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pINDUCER11-NUAK1#2 This study N/A
pINDUCER11-NUAK1#3 This study N/A
Chemicals, Peptides, and Recombinant Proteins
Stearyl-R8-KRPKGILKKRS peptide LifeTein N/A
FITC-Stearyl-R8 peptide LifeTein Cat# LT12013
BAY-880, IUPAC name 7-cyclopentyl-5-ethyl-2-
(1H-pyrrol-2-yl)imidazo[5,1-f][1,2,4]triazin-
4(3H)-one
Bayer European Patent EP1399439B1, example 43
NUAK1i (structurally related to BAY-880) Bayer N/A
Calyculin A Santa Cruz Biotechnology Cat# sc-24000
Pladienolide B Santa Cruz Biotechnology Cat# sc-391691
HTH-01-015 Selleckchem Cat# S7318
WZ4003 Selleckchem Cat# S7317
P276-00 Selleckchem Cat# S8058
LDC000067 Selleckchem Cat# S7461
NVP-2 Tocris/Bio-Techne Cat# 6535/5
4-Thiouridine (4sU) Sigma-Aldrich Cat# T4509
BX795 Sigma-Aldrich Cat# 204001
Okadaic acid Sigma-Aldrich Cat# 459620
Flavopiridol Sigma-Aldrich Cat# F3055
4-hydroxytamoxifen Sigma-Aldrich Cat# H7904
Doxycycline Sigma-Aldrich Cat# D9891
Cholera toxin Sigma-Aldrich Cat# C8052
Insulin Sigma-Aldrich Cat# I9278
Hydrocortisone Sigma-Aldrich Cat# H0396
Protease inhibitor cocktail Sigma-Aldrich Cat# P8340
Phosphatase inhibitor cocktail 2 Sigma-Aldrich Cat# P5726
Phosphatase inhibitor cocktail 3 Sigma-Aldrich Cat# P0044
Duolink In Situ PLA Probe Anti-Rabbit PLUS Sigma-Aldrich Cat# DUO92002
Duolink In Situ PLA Probe Anti-Mouse MINUS Sigma-Aldrich Cat# DUO92004
Duolink In Situ Detection Reagents Red Sigma-Aldrich Cat# DUO92008
Puromycin InvivoGen Cat# ant-pr-1
Benzonase Merck Millipore Cat#70664-3
DAPI Roth Cat# 6335.1
RNase A Roth Cat# 7156.1
RNase H NEB Cat# M0297
EcoRI NEB Cat# R0101
BamHI NEB Cat# R0136
BsrGI NEB Cat# R0575
HindIII NEB Cat# R0104
SspI NEB Cat# R0132
XbaI NEB Cat# R0145
XhoI NEB Cat# R0146
Dynabead Protein A Thermo Fisher Scientific Cat# 10002D
Dynabead Protein G Thermo Fisher Scientific Cat# 10004D
Dynabeads MyOne Streptavidin T1 Thermo Fisher Scientific Cat# 65601
Dithiothreitol (DTT) Thermo Fisher Scientific Cat# 20291
Lipofectamine 2000 Thermo Fisher Scientific Cat# 11668019
(Continued on next page)
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Lipofectamine RNAiMAX Thermo Fisher Scientific Cat# 13778-150
ibidi Mounting Medium Ibidi Cat# 50001
Odyssey Blocking Buffer in TBS LI-COR Biosciences Cat# 927-50000
peqGOLD Trifast PeqLab/WVR Cat# 30-2010
Critical Commercial Assays
Quant-iT PicoGreen dsDNA assay Thermo Fisher Scientific Cat# P7589
Quant-iT RiboGreen RNA Assay Kit Thermo Fisher Scientific Cat# R11490
NEBNext ChIP-Seq Library Prep Master Mix
Set for Illumina
NEB Cat# E6240
NEBNext Ultra Directional RNA Library Prep
Kit for Illumina
NEB Cat# E7420
NEBNext Ultra II RNA Library Prep Kit for
Illumina
NEB Cat# E7770
NEBNext rRNA Depletion Kit NEB Cat#E6310
NEBNext Ultra II RNA Library Prep Kit for
Illumina
NEB Cat# E7770
RNeasy MinElute Cleanup Kit QIAGEN Cat#74204
miRNeasy Mini Kit QIAGEN Cat# 217004
NextSeq 500/550 High Output Kit v2 Illumina Cat# FC-404-2005
Deposited Data
Raw and analyzed data This study GEO: GSE129925
Raw and analyzed data Walz et al., 2014 GEO: GSE44672
Raw and analyzed data De Magis et al., 2019 GEO: GSE115957
Raw and analyzed data Olson et al., 2018 GEO: GSE89384
Human reference genome GRCh37/hg19 Genome Reference Consortium https://support.illumina.com/sequencing/
sequencing_software/igenome.html
Raw images, proteomic data This study Mendeley Data https://dx.doi.org/10.17632/
rm56h9msym.1
Experimental Models: Cell Lines
U2OS ATCC RRID: CVCL_0042
U2OS MYC-ER Liu et al., 2012 N/A
HEK293TN ATCC RRID: CVCL_UL49
PlatE ATCC RRID: CVCL_B488
HeLa ATCC RRID: CVCL_0030
KPC Siveke lab N/A
IMR5 Eggert lab RRID: CVCL_1306
NGP Eggert lab RRID: CVCL_2141
SH-SY5Y ATCC RRID: CVCL_0019
Kelly Eggert lab RRID: CVCL_2092
MCF10A ATCC RRID: CVCL_0598
SKNAS ATCC RRID: CVCL_1700
NIH 3T3 ATCC RRID: CVCL_0594
Oligonucleotides
Primers for ChIP, DRIP and qPCR: Table S2 This study N/A
Primers for cloning: Table S3 This study N/A
Primers for DRIP: Table S4 This study N/A
mirE_shNUAK1#1: TGCTGTTGACAGTGAGCGC
ACGGTGGATGCTGATGGTGAATAGTGAAG
CCACAGATGTATTCACCATCAGCATCC
ACCGTATGCCTACTGCCTCGGA
This study N/A
(Continued on next page)
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mirE_shNUAK1#2: TGCTGTTGACAGTGAG
CGAGCTGAAGAAATCCAAGAAAGATAG
TGAAGCCACAGATGTATCTTTCTTGGA
TTTCTTCAGCGTGCCTACTGCCTCGGA
This study N/A
mirE_shNUAK1#3: TGCTGTTGACAGTG
AGCGATAGGGATTTACTGGCATGGTATA
GTGAAGCCACAGATGTATACCATGCCAG
TAAATCCCTACTGCCTACTGCCTCGGA
This study N/A
ON-TARGETplus Non-targeting Pool Dharmacon / Horizon Discovery Cat# D-001810-10-50
ON-TARGETplus Human NUAK1 siRNA -
SMARTpool
Dharmacon / Horizon Discovery Cat# L-004931-01-0005
ON-TARGETplus Human PPP1R10 siRNA –
SMARTpool
Dharmacon / Horizon Discovery Cat# L-011358-00-0005
PPP1R10 Silencer Select siRNA Thermo Fisher Scientific Cat# 4392420 - s328
Recombinant DNA
pBABE-puro Liu et al., 2012 N/A
pBABE-Nuak1-FLAG-NT-puro This study N/A
pBABE-Nuak1-FLAG-CT-puro This study N/A
pBABE-Nuak1-HA-NT-puro This study N/A
pBABE-Nuak1-HA-CT-puro This study N/A
pcDNA3 Thermo Fisher Scientific Cat# V79020
pcDNA5/TO-Flag-mPNUTS Skalnik Lab Lee et al., 2010
pcDNA3-Ppp1r10-HA-wt-puro This study N/A
pcDNA3-Ppp1r10-HA-S313A-puro This study N/A
pcDNA3-Ppp1r10-HA-S313D-puro This study N/A
pcDNA3-Ppp1r10-HA-S313E-puro This study N/A
pINDUCER11 Trono lab Meerbrey et al., 2011
pINDUCER11-NUAK1#1 This study N/A
pINDUCER11-NUAK1#2 This study N/A
pINDUCER11-NUAK1#3 This study N/A
psPAX2 Addgene Cat# 12260
pMD2.G Addgene Cat# 12259
Software and Algorithms
Max Quant Cox and Mann, 2008 http://www.coxdocs.org/doku.php?
id=:maxquant:start
Spotfire TIBCO N/A
Image Studio Lite v5.2.5 LI-COR Biosciences N/A
ImageJ v1.49 Schneider et al., 2012 https://imagej.net/ImageJ
Prism v6 GraphPad N/A
Integrated Genome Browser v9.0.2 Freese et al., 2016 https://bioviz.org/
Bowtie v2.3.5 Langmead et al., 2009 http://bowtie-bio.sourceforge.net/index.shtml
TopHat v2.1.1 Kim et al., 2013 https://ccb.jhu.edu/software/tophat/index.shtml
Bedtools v2.26.0 Quinlan, 2014 https://github.com/arq5x/bedtools2/releases
SAMtools v1.3 Li et al., 2009 http://samtools.sourceforge.net
DeepTools v2.3.5-3-2c5f94d Ramı´rez et al., 2016 https://deeptools.readthedocs.io/en/develop/
index.html
ngsPlot v2.61 Shen et al., 2014 https://github.com/shenlab-sinai/ngsplot/
R (v 3.4.4 or 3.5.1) R Core Team, 2017 https://www.r-project.org/
TreeView 1.16r4 Saldanha, 2004 http://jtreeview.sourceforge.net/
(Continued on next page)
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FastQC v0.11.5 N/A http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/
GSEA v2.2 Subramanian et al., 2005 http://software.broadinstitute.org/gsea/index.jsp
MSigDB database v6.0 Liberzon et al., 2011 http://software.broadinstitute.org/gsea/msigdb/
index.jsp
macs v1.4.1 Zhang et al., 2008 https://taoliu.github.io/MACS/
AmiGO v2 Carbon et al., 2009 http://amigo.geneontology.org/amigo
Perseus v1.6.2.3 Tyanova et al., 2016 https://maxquant.net/perseus/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Martin
Eilers (martin.eilers@biozentrum.uni-wuerzburg.de). There are restrictions to the availability of BAY-880 due to the lack of an external
centralized repository for its distribution and our need to maintain the stock. All other unique reagents generated in this study are
available from the Lead Contact without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Employed cell lines
U2OS, HeLa, HEK293TN and PlatE human female; KPC andNIH 3T3mousemale cell lines were cultured at 37C (5%CO2) in DMEM
(Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich). SKNAS, SH-SY5Y, Kelly (female) and
NGP, IMR-5 (male) human neuroblastoma cell lines were grown in RPMI-1640 (Thermo Fisher Scientific) supplemented with 10%
fetal bovine serum. MCF10A female human cell line was cultured in DMEM/F-12 (Thermo Fisher Scientific) supplemented with
5% horse serum (Sigma-Aldrich), 100 mg/ml cholera toxin, 10 mg/ml insulin, 0.5 mg/ml hydrocortisone and 20 ng/ml EGF. All cell lines
were verified by single tandem repeat profiling and routinely tested for mycoplasma contamination.
Cell culture treatments
For siRNA transfection, 10 ml of 20 nM siRNA were mixed with 10 ml Lipofectamine RNAiMAX in 1 mL OptiMEM (Thermo Fisher Sci-
entific). After 5 min incubation at RT, the mixture was added to cells overnight.
For plasmid transfection, FBS concentration was first adjusted to 2%. 10 mg DNA were then mixed with 10 ml Lipofectamine or
polyethylenimine (PEI, Sigma-Aldrich) in 1 mL OptiMEM. After 20 min incubation at RT, the mixture was added to cells overnight.
For retroviral infection, PlatE cells were cultured till 80% confluence, then the FBS concentration was adjusted to 2%. 30 mg DNA
were then mixed with 24 ml PEI in 1 mL OptiMEM. After 20 min incubation, the mixture was added to cells overnight. Cells were then
cultured with 10% FBS for two days, collecting virus-containing supernatant every 24 h. Dead cells were removed from supernatant
by employing 0.45 mmfilters. Target cells were then cultured to 80% confluence and added 3mL supernatant, 2 mL DMEMwith 10%
FBS and 4 mg/ml Polybrene (Sigma-Aldrich).
For lentiviral infection, HEK293TN cells were cultured to 80% confluence, then the FBS concentration was adjusted to 2%. 8 mg
vector DNA, 8 mg psPAX2 and 2 mg pMD2.G were then mixed with 24 ml polyethylenimine in 1 mL OptiMEM. After 20 min incubation,
the mixture was added to cells overnight. Cells were then cultured with 10% FBS for two days, collecting virus-containing superna-
tant every 12 h. Dead cells were removed from the supernatant by employing 0.45 mm filters. Target cells were then cultured to 30%
confluence and added 500 ml supernatant, 5 mL DMEM with 10% FBS and 6 ug/ml Polybrene.
For peptide treatment, peptides were dissolved in water and added directly to cell culture medium. Peptides were designed with a
stearyl-8xArg tail to facilitate cell penetration. GILK peptide sequence encompasses residues 395 to 407 within the GILK site #1 of
NUAK1 (Zago´rska et al., 2010).
BAY-880 – originally described in the European Patent EP 1399439B1 – was identified as a potent NUAK1 inhibitor by Bayer in an
ultraHTS campaign screening 2.6 million compounds. The assay in the primary HTS used recombinant NUAK1 to phosphorylate a
synthetic peptide. The phospho-readout was by TR-FRET. Primary hits were confirmed in an orthogonal ADP-Glo assay.
METHOD DETAILS
Immunofluorescence
Depending on the downstream application, cells were seeded in m-Slide 8-well or 18-well chambers (Ibidi) or in 96-well mclear plates
(Greiner). At the appropriate time point, cells were fixed with 4% PFA in PBS and permeabilized at least 20 min in ice-cold 100%
methanol. Cells were then incubated at least 30 min in 5% BSA in PBS (‘‘blocking solution’’). First antibody in blocking solutione5 Molecular Cell 77, 1322–1339.e1–e11, March 19, 2020
was then added overnight. Wells were washed 3x with PBS, then added 1:1000 Alexa Fluor-conjugated second antibody in blocking
solution for 1 h. 1:1000 DAPI in blocking solution was then added to wells were then added of for 5 min and washed 3x with PBS.
Wells were added of ibidi Mounting Medium or PBS and stored at 4C up to one week. Proximity ligation assays (PLA) were carried
out using the Duolink In Situ Kit according to the manufacturer’s protocol. Imaging was performed with a Nikon Eclipse-Ti confocal
microscope (equipped with the NIS-elements AR 3.22.15 software) or with the Operetta High-Content Imaging System
(Perkin Elmer).
Cell fractionation
Plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were collected with a scraper
and pelleted by 250 g centrifugation for 40 min. Pellets were resuspended in 1 mL sucrose buffer (10 mM HEPES pH 7.9, 0.34 M
Sucrose, 3 mM CaCl2, 2 M magnesium acetate, 0.1 mM EDTA) with 0.5% NP-40 and incubated on a rotator for 10 min. Nuclei
were then pelleted by 3900 g centrifugation for 20 min. The supernatant was collected as cytoplasmic fraction, while pellets were
washed in 1 mL sucrose buffer and pelleted again by 3900 g centrifugation for 20 min. Pelleted nuclei were resuspended in 1 mL
nucleoplasmic extraction buffer (20mM HEPES pH 7.9, 3 mM EDTA, 10% glycerol, 150 mM potassium acetate, 1.5 mMMgCl2), ho-
mogenized with a Dounce homogenizer and, after 40min incubation, homogenized again. When applicable, samples were treated at
this stage for 15 min with 20 mg RNase A at 37C. Samples were then incubated 1 h with 25U benzonase and then centrifuged by
13000 rpm for 30 min. The supernatant was collected as nucleoplasmic fraction, while pellets were resuspended in 150 mM HEPES
pH 7.9, 1.5 mMMgCl2, 150 mM potassium acetate with 2.5 U benzonase. After incubation for 30 min on a rotating wheel at RT, sam-
ples were pelleted and supernatants were collected as chromatin fraction.
Immunoblotting
Whole-cell extracts were prepared using RIPA buffer (50 mM Tris pH 7.4, 150 mMNaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1%
NP-40). Briefly, plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were
collected with a scraper and pelleted by 13000 rpm centrifugation for 5 min. Pellets were resuspended in RIPA buffer and incubated
30 min on ice. Tubes were then centrifuged at 13000 rpm for 5 min and supernatants were collected for further use. Protein lysates
were quantified according to standard procedures (i.e., Bradford assay or bicinchoninic acid assay), separated employing Bis-Tris
acrylamide gels and transferred on PVDF membranes (Merck-Millipore). Membranes were blocked 1 h with 20% Odyssey Blocking
Buffer in TBS, incubated overnight with listed first antibodies in 20% Odyssey Blocking Buffer in TBS, washed 3x with TBS-T, incu-
bated 1 h with IRDye 680RD or 800CW second antibodies, washed 3x with TBS-T and imaged and quantified with the Odyssey CLx
Infrared Imaging System (LI-COR Biosciences).
Co-immunoprecipitation
Plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were collected with a scraper
and pelleted by 1500 rpm centrifugation for 10 min. Pellets were lysed in HEGN buffer (20 mM HEPES-KOH pH 7.8, 0.2 mM EDTA,
0.1% NP-40, 10 mM sodium pyrophosphate, 140 mM KCl, 10% glycerol, containing 1:1000 protease and phosphatase inhibitors),
sonicated with a Branson sonifier 4x5 s at 20% amplitude and incubated 30 min on ice. Lysates were cleared upon repeated cen-
trifugations and quantified according to standard procedures (i.e., Bradford assay of bicinchoninic acid assay). 1%–2% lysate was
kept as input control. Unless otherwise noted, lysates were added 1 mg antibody (including a sample with 1 mg IgG control antibody,
Sigma-Aldrich) and incubated 3-6 h on a rotating wheel at 4C. 7.5 ml protein A/G Dynabeads per immunoprecipitation were washed
three times in HEGN, then incubatedwith the lysate overnight. Beadswerewashed three timeswith HEGN, then resuspended in 60 ml
1X L€ammli buffer and processed for immunoblotting.
Proteomic analysis of NUAK1 interactors
U2OS cells stably expressing N-terminal or C-terminal FLAG-tagged murine Nuak1 (or empty pBABE vector) were harvested and
subjected to standard immunoprecipitation with minor modifications. Briefly, lysates were incubated overnight with anti-FLAG M2
magnetic beads (Sigma-Aldrich) and immunoprecipitates were eluted with 150ng/ml 3X FLAG peptide (Sigma-Aldrich) and
acetone-precipitated. 5% of samples were loaded on Bis-Tris gels for checking actual FLAG-Nuak1 immunoprecipitation by immu-
noblotting or silver staining.
Acetone-precipitated samples were dissolved in NuPAGE LDS sample buffer (Thermo Fisher Scientific), reduced with 50 mM DTT
at 70C for 10min and alkylated with 120mM Iodoacetamide at room temperature for 20min. Separation was performed onNuPAGE
Novex 4%–12%Bis-Tris gels (Thermo Fisher Scientific) withMOPS buffer according tomanufacturer’s instructions. After washing 3x
with water, gels were stained for 1h with Simply Blue Safe Stain (Thermo Fisher Scientific). After washing with water for 1 h, each gel
lane was cut into 15 slices, destained with 30% acetonitrile in 0.1 M NH4HCO3 (pH 8), shrunk with 100% acetonitrile, and dried in a
vacuum concentrator 5301 (Eppendorf). Samples were then digested with 0.1 mg trypsin per gel band overnight at 37C in 0.1 M
NH4HCO3 (pH 8). Peptides were extracted from the gel slices with 5% formic acid.
NanoLC-MS/MS analyses were performed on an LTQ-Orbitrap Velos Pro (Thermo Fisher Scientific) equipped with an EASY-Spray
Ion Source and coupled to an EASY-nLC 1000 (Thermo Fisher Scientific). Peptides were loaded on a trapping column (2 cm x 75 mm
ID. PepMap C18, 3 mm particles, 100 A˚ pore size) and separated on an EASY-Spray column (25 cm x 75 mm ID, PepMap C18, 2 mmMolecular Cell 77, 1322–1339.e1–e11, March 19, 2020 e6
particles, 100 A˚ pore size) with a 30-minute linear gradient from 3% to 30% acetonitrile and 0.1% formic acid. MS scans were ac-
quired in the Orbitrap analyzer with a resolution of 30,000 at m/z 400, MS/MS scans were acquired in the Orbitrap analyzer with a
resolution of 7,500 at m/z 400 using HCD fragmentation with 30% normalized collision energy. A TOP5 data-dependent MS/MS
method was used; dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 30 s; singly charged pre-
cursors were excluded from selection. Minimum signal threshold for precursor selection was set to 50,000. Predictive AGC was
used with AGC target a value of 1e6 for MS scans and 5e4 for MS/MS scans. Lock mass option was applied for internal calibration
in all runs using background ions from protonated decamethylcyclopentasiloxane (m/z 371.10124).
Raw MS data files were analyzed with MaxQuant version 1.6.2.2 (Cox and Mann 2008). Database search was performed with
Andromeda, which is integrated in the utilized version ofMaxQuant. The search was performed against the UniProt Human database.
Additionally, a database containing common contaminants was used. The search was performed with tryptic cleavage specificity
with 3 allowed miscleavages. Protein identification was under control of the false-discovery rate (1% FDR on protein and peptide
level). In addition to MaxQuant default settings, the search was performed against following variable modifications: Protein N-termi-
nal acetylation, Gln to pyro-Glu formation (N-term. Gln) and oxidation (Met). Carbamidomethyl (Cys) was set as fixed modification.
For protein quantitation, the LFQ intensities were used (Cox et al., 2014). Proteins with less than two identified razor/unique peptides
were dismissed.
Further data analysis was performed using R scripts developed in-house. LFQ intensities were used and missing LFQ intensities in
the control samples were imputed with values close to the baseline. Data imputation was performed with values from a standard
normal distribution with a mean of the 5% quantile of the combined log10-transformed LFQ intensities and a standard deviation
of 0.1. For the identification of significantly co-immunoprecipitated proteins, mean log2 transformed protein ratio were calculated
from the two replicate experiments and boxplot outliers were identified in intensity bins of at least 300 proteins. Log2 transformed
protein ratios of CoIP versus control with values outside a 1.5x (potential) or 3x (extreme) interquartile range (IQR), respectively,
were considered as significantly co-immunoprecipitated. GO term analyses of the dataset were performed with the web-available
tool AmiGO (Carbon et al., 2009).
Label-free phosphoproteomics
U2OS cells were treated for 2 h with 10 mM BAY-880, 10 mM HTH-01-015 or DMSO, then plates were washed in ice-cold PBS (con-
taining 1:1000 protease and phosphatase inhibitors). Cells were then collected with a scraper, pelleted by 1500 rpm centrifugation for
10 min and flash-frozen in liquid nitrogen.
Samples were then digested in trifluoroacetic acid (TFA) and phosphopeptide-enriched according to the EasyPhos protocol with
some changes (Humphrey et al., 2015).
Pellets were first resuspended in GdmCl lysis buffer (6 M GdmCl, 100 mM Tris pH 8.5, 10 mM TCEP, 40 mM CAA). Samples were
then added 50 mM DTT, shaken 10 min at 70C, added 120 mM iodoacetamide and incubated 30 min in the dark. After adding 50 ml
1M ABC buffer, samples were added 4X acetone and proteins precipitated overnight. After centrifugation at 2000 g for 15min, pellets
were washed 3x with cold acetone and dried up. Pellets were then resuspended in 750 ml digestion buffer (10% TFA in 100mM ABC
buffer) and sonified in a Bioruptor (5 cycles of 30sec). Samples were added 1:100 LysC and incubated 1 h at 37C, then added 10 mg
sequencing-grade modified trypsin (Promega) and incubated overnight at 37C upon shaking. Digested samples were centrifuged at
16000 g for 20 min, then lyophilized overnight. Samples were dissolved in 2% ACN, 0.5% FA with the help 3x30 s Bioruptor cycles
and 20 min shaking. Samples were then centrifuged for 5 min at 5000 g and cleaned up with Sep Pak C18 cartridges (Waters). 10 ml
sample was collected for protein measurement, while the rest dried up lyophilized. Phosphopeptides were enriched with PhosphTio
tips 3 mg/ 200 ml (GLSciences) and eluted in 150 ml 15% ACN, 5% ammoniumhydroxide before overnight lyophilization. Samples
were redissolved in 100 ml 200 mM citric acid with 20 ml ACN and 1 ml formic acid shortly before NanoLC-MS/MS measurement.
NanoLC-MS/MS analyses were performed on an Orbitrap Fusion (Thermo Fisher Scientific) equipped with a PicoView Ion Source
(New Objective) and coupled to an EASY-nLC 1000 (Thermo Fisher Scientific). Peptides were loaded on capillary columns (PicoFrit,
30 cm x 150 mm ID, New Objective) self-packed with ReproSil-Pur 120 C18-AQ, 1.9 mm (Dr. Maisch) and separated with a 90-minute
linear gradient from 3% to 40% acetonitrile and 0.1% formic acid and a flow rate of 500 nl/min.
Both MS andMS/MS scans were acquired in the Orbitrap analyzer with a resolution of 60,000 for MS scans and 15,000 for MS/MS
scans. HCD fragmentation with 35% normalized collision energy was applied. A Top Speed data-dependent MS/MS method with a
fixed cycle time of 3 s was used. Dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 45 s; singly
charged precursors were excluded from selection. Minimum signal threshold for precursor selection was set to 50,000. Predictive
AGC was used with AGC a target value of 2e5 for MS scans and 5e4 for MS/MS scans. EASY-IC was used for internal calibration.
Raw MS data files were analyzed with MaxQuant version 1.5.7.4. Database search was performed with Andromeda, which is in-
tegrated in the utilized version of MaxQuant. The search was performed against the UniProt Human database. Additionally, a data-
base containing common contaminants was used. The search was performed with tryptic cleavage specificity with 3 allowed mis-
cleavages. Protein identification was under control of the false-discovery rate (1% FDR on protein and peptide level). In addition to
MaxQuant default settings, the search was performed against following variable modifications: oxidation (Met), Gln to pyro-Glu for-
mation (N-term. Gln) and Phospho (STY). Carbamidomethyl (Cys) was set as fixed modification. For protein quantitation, the LFQ
intensities were used (Cox et al., 2014). Proteins with less than two identified razor/unique peptides were dismissed. Intensities
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Spike-in SILAC phosphoproteomics
U2OS cells were transfected overnight with siRNA targeting NUAK1 and grown for further 48 h after transfection start in standard
DMEM. In parallel, SILAC reference cells were cultured with SILAC media (DMEM (-Lys, Arg, Gln), 10% dialyzed FBS, 1X LysH,
1XArgH, 1XGlnH) and grown until complete heavy label incorporation (> 98%). At themoment of harvesting, cells were then collected
with a scraper, pelleted by 1500 rpm centrifugation for 10 min and flash-frozen in liquid nitrogen.
Cell pellets were lysed with 8 M urea, 2 mM EDTA in 50 mM Tris HCl buffer, containing protease and phosphatase inhibitor cock-
tails. Cells were sonicated for 20 s with 2 pulses at 60% power (Sonoplus HD2070, Bandelin, Germany).
Protein concentration was determined by Bradford colorimetric assay. 1.75mg of each sample wasmixed with an equal amount of
SILAC reference sample and proteins were reduced in DTT 2mM for 30min at 25C and successively free cysteines were alkylated in
11 mM iodoacetamide for 20 min at room temperature in the darkness.
LysC digestionwas performed by adding LysC (Wako) in a ratio 1:40 to the sample and incubating it for 16 h under gentle shaking at
30C. After LysC digestion, the samples were diluted 3 times with 50 mM ammonium bicarbonate solution; afterward, trypsin was
added in a 1:50 ratio and samples were incubated 4 h at 30C. 15 mg of digested samples were desalted on STAGE Tips, dried
and reconstituted to 25 ml of 0.5% acetic acid in water (Nguyen et al., 2018; Rappsilber et al., 2003).
The rest of the peptide mixtures was desalted on 3 mL SepPak C18 columns according to manufacturer’s instructions and then
dried under vacuum. Samples were dissolved before enrichment in buffer C.
Pre-packed 200 ml TiO2 Tips (GLSCience, Japan) were first washed with 20 ml of buffer B (80% ACN with 0.1% trifluoroacetic acid)
and then 20 ml of buffer C. Then peptide sample was loaded on the tip and the beadswashedwith 20 ml of buffer C and 20 ml of buffer B.
For elution, 20 ml of 5% ammonium hydroxide in water were used. The eluate was acidified and purified STAGE Tips, dried and
reconstituted to 7 ml of 0.5% acetic acid in water (Rappsilber et al., 2003).
5 ml were injected on a LC-MS/MS system (NanoLC-Ultra [Eksigent] and LTQ-Orbitrap Velos (Thermo Fisher Scientific), using a
240 min gradient ranging from 5% to 40% of solvent B (80% acetonitrile, 0.1% formic acid; solvent A 5 5% acetonitrile, 0.1% formic
acid). For the chromatographic separation, a 20-cm-long capillary (75 mm inner diameter) was packed with 3 mm C18 beads (Re-
prosilPur C18 AQ, Dr. Maisch). On one end of the capillary a nanospray tip was generated using a laser puller (P-2000 Laser Based
Micropipette Puller, Sutter Instruments), allowing fretless packing. The nanospray source was operated with a spray voltage of 2.1 kV
and an ion transfer tube temperature of 260C. Data were acquired in data dependent mode, with one surveyMS scan in the Orbitrap
mass analyzer (resolution 60,000 at m/z 400) followed by up to 20 MS\MS scans in the ion trap on the most intense ions (intensity
threshold, 500 counts). To improve the fragmentation of phosphopeptides, the multistage activation algorithm in the Xcalibur soft-
ware was enabled for each MS/MS spectrum using the neutral loss values of 97.97, 48.99, 32.66 and 24.49 m/z units. Once selected
for fragmentation, ions were excluded from further selection for 30 s, to increase new sequencing events.
Raw data was analyzed using the MaxQuant proteomics pipeline (v. 1.4.0.5) and the built-in Andromeda search engine (Cox et al.,
2011) with the Uniprot Human database. Carbamidomethylation of cysteines was chosen as fixed modification, oxidation of methi-
onine and acetylation of N terminus were chosen as variable modifications. The search engine peptide assignments were filtered at
1%FDR and the featurematch between runs was not enabled; second peptide feature was enabled, while other parameters were left
as default. For SILAC samples, two ratio counts were set as threshold for quantification.
The MaxQuant output was further analyzed in Perseus v1.6.2.3 for Windows 10 (Tyanova et al., 2016). Filtering was performed to
exclude contaminants, reverse proteins, peptides with Andromeda score < 40, peptides with localization probability% 0.75, pep-
tides with posterior error probabilityR 0.05, and any peptide that did not present all valid values in at least one group of the dataset.
Differentially phosphorylated sites were assessed by two-sided t test with permutation-based FDR truncation, using the default pa-
rameters, on the transformed log2 of the inverted ratio H/L normalized siRNA NUAK1 against the transformed log2 of the inverted
ratio H/L normalized control. GeneOntology (GO) terms (TheGeneOntology Consortium, 2019) represented in the differentially phos-
phorylated sites that presented p value% 0.05 were evaluated with the in-built Fisher exact test. PPP1CA, PPP1CB, PPP1CC inter-
actome curated in IntAct database (Orchard et al., 2014) were merged, filtered for human proteins and connections, and overlapped
with differentially phosphorylated sites that presented p value% 0.05 in R version 3.4.4 for macOS High Sierra (R Core Team, 2013).
The differentially phosphorylated sites, the GO terms, and PPP1C interactors were graphically represented using ggplot2 (Wickham,
2016) in R version 3.4.4 for macOS High Sierra (R Core Team, 2013).
Tandem Mass Tag (TMT) phosphoproteomics
U2OS cells were transfected overnight with a siRNA pool targetingNUAK1 (or a non targeting control pool) and grown for further 48 h
after transfection start in standard DMEM or treated 2 h with 10 mM BAY-880 (or DMSO) and then immediately washed with PBS to
stop the treatment. Lysis buffer (2% SDS in 50 mM HEPES buffer, pH 8.5) was then immediately added to the plates and cells
collected with a scraper. Lysates were incubated for 5 min at 95C and subsequently placed on ice for 5 min. Finally, lysates
were sonicated 30 s (5 s on/10 s off) with a Branson sonifier and protein concentration was determined using the BCA Protein Assay
Kit (Thermo Scientific).
A total of 500 mg protein of each samplewas precipitated using chloroform-methanol. Proteinswere reconstituted in 8Murea. Reduc-
tionofCyswasperformedusing10mMDTTat 30C for 30min. The reactionwasquenchedby50mMchloroacetamide for 30min.Sam-
pleswere diluted to 1.6Murea using 50mMTris-HCl (pH 8). Digestionwas performed by adding trypsin (Promega) at a 1:50 enzyme-to-
substrate ratio and incubated overnight at 30C. Digests were acidified by adding formic acid to 0.5%, centrifuged to pellet insolubleMolecular Cell 77, 1322–1339.e1–e11, March 19, 2020 e8
matter, anddesaltedusing tC18RPsolid-phaseextractioncartridges (WatersCorp.;washsolvent:0.1%formicacid (FA); elutionsolvent:
0.1% FA in 50% acetonitrile). Eluates were frozen at 80C and dried by vacuum centrifugation.
Desalted peptides (100 mg per experimental condition) were reconstituted in 50 mM HEPES (pH8.5) and labeled by tandem mass
tags (Thermo Fisher) as described (Zecha et al., 2019). TMT labeled samples were combined and enriched for phosphopeptides us-
ing immobilized metal affinity chromatography as described (Ruprecht et al., 2015). Subsequent high pH reversed phase fraction-
ation of phosphopeptides was performed as described (Ruprecht et al., 2017). The resulting six phosphopeptide fractions were dried
down and stored at 20C until LC-MS measurement.
Nanoflow LC-MS/MS was performed on an Ultimate 3000 RSLCnano chromatography system coupled online to an Orbitrap
Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific). Phosphopeptides were reconstituted in 50 mM citric acid,
0.1% FA and loaded on a 75 mm x45cm analytical column (packed in-house with 3 mm C18 resin; Reprosil Gold, Dr. Maisch). Phos-
phopeptides were separated using a 90-min linear gradient from 4% to 32% LC solvent B (0.1% FA, 5%DMSO in ACN) at a flow rate
of 300 nl/min. The mass spectrometer was operated in data dependent and positive ionization mode. MS1 spectra were recorded at
a resolution of 60,000 using an automatic gain control (AGC) target value of 4e5 and a maximum injection time (maxIT) of 50 ms. For
peptide identification, peptides were fragmented by collision-induced dissociation (CID) at 35% normalized collision energy with
multistage activation in the ion trap and using an AGC target value of 5e4 and a maxIT of 60ms. Fragment ions were recorded at
30,000 resolution in the Orbitrap. For TMT quantification peptides were fragmented in the ion trap as above using an AGC of
1.2e5 and a maxIT of 120ms and fragment ions were subjected to synchronous precursor selection (SPS) and fragmented in the
HCD cell at a normalized collision energy of 55% and the resulting MS3 spectrum was recorded in the Orbitrap at a resolution
of 50,000.
Peptide identification and quantification were performed using MaxQuant (version 1.6.2.10) with its built-in search engine
Andromeda. Tandemmass spectra were searched against the UniProt Human database supplemented with common contaminants.
The search was performed with carbamidomethylated cysteine and TMT-modified lysine side chain and peptide N-termini as fixed
modifications and oxidation (Met), N-terminal protein acetylation and phosphorylation (STY) as variable modifications. Results were
filtered to 1% false discovery rate (FDR) on peptide spectrum match (PSM) level. The MaxQuant results was further analyzed in
Perseus v1.6.1.1, also part of the MaxQuant software suite. Hits to the reverse and contaminant databased were removed. Relative
abundances of phosphopeptides were determined using TMT reporter ion intensities from all PSMs and log2 transformed intensity
value are reported throughout. Phosphopeptides were filtered for a minimum of 2 or 3 valid values in the four biological replicates.
Differential phosphopeptide abundance was assessed by two-sided t tests with permutation-based FDR truncation, using default
parameter for s0 (value of 0.1) and 1% FDR. Enrichment analysis of significantly regulated phosphopeptides for biological processes
was performed using the Gene Ontology database. Only phosphosites with at least 3 valid values out of 4 biological replicates were
considered.
Chromatin IP (ChIP)
The ChIP protocol was performed as described before (Herold et al., 2019) with minor modifications. Briefly, plates were added 1%
formaldehyde (Roth) for 5-10 min to crosslink proteins to DNA, then added 1 M glycine (Roth) for 5 min and finally washed in ice-cold
PBS (containing 1:1000 protease and phosphatase inhibitors). Cells were then collected with a scraper and pelleted by 1500 rpm
centrifugation for 5 min at 4C. Pellets were resuspended in lysis buffer I (5 mM PIPES pH 8, 85 mM KCl, 0.5% NP-40) for 20 min
on ice and again collected by 1500 rpm centrifugation for 5 min at 4C. Pellets were resuspended in lysis buffer II (50 mM HEPES
pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) for 10 min on ice and then sonified
with either a Branson sonifier (20 min, 10 s on/30 s off, 25% amplitude) or a Covaris M220 instrument (30 min, duty factor 12, cy-
cles/burst 220). 25 ml of sonified samples were decrosslinked (see below), DNA was purified with phenol/chloroform extraction
and run in a 2% agarose gel to confirm sonication efficiency. 1% of sample was kept as input control.
15 ml each of protein A and G Dynabeads per immunoprecipitation were washed three times in 5% BSA in PBS (BSA-PBS), then
added with 3 ml of antibody, then incubated overnight on a rotating wheel at 4C. Beads were washed three times in BSA-PBS, then
added to the samples and incubated overnight on a rotating wheel at 4C. Immunoprecipitates were then washed 3x with washing
buffer I (20mM Tris HCl pH 8, 150mMNaCl, 2mM EDTA, 0,1% SDS, 1% Triton X-100), 3x with washing buffer II (20mM Tris HCl pH 8,
500mMNaCl, 2mM EDTA, 0,1% SDS, 1% Triton X-100), 3x with ChIP wash buffer III (10mM Tris HCl pH 8, 250mM LiCl, 1mM EDTA,
1%NP40, 1%Deoxycholic acid sodium salt), incubating the samples 5min on ice between each wash. Samples were then eluted by
adding 2x 150-250 ml elution buffer (1% SDS, 50mMNaHCO3 in TE, pH 8.0) and incubated for 15 min on a rotating wheel @RT. Sam-
ples were added 10 mg RNase A and incubated for 1 h at 37C. Samples were then de-crosslinked by incubating overnight at 65C
and finally incubated with 2 mg proteinase K for 2 h at 45C. Samples were then purified with phenol/chloroform extraction and
quantified with qPCR. Where applicable, lysates were treated with 20 mg RNase A for 15 min at 37C before incubating them with
antibody-conjugated beads.
To perform ChIP followed by deep sequencing (ChIP-Seq), 100 million cells per condition were collected and processed as for a
standard ChIP. Samples were then processed to build libraries for deep sequencing with the NEBNext ChIP-Seq Library PrepMaster
Mix Set for Illumina according tomanufacturer’s instruction. To performChIP-Seq with exogenous reference genome spike-in (ChIP-
RX), 10 million mouse NIH 3T3 untreated cells were fixed, harvested, resuspended in lysis buffer I and added to every sample in lysis
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DNA-RNA immunoprecipitation (DRIP)
The DRIP protocol was derived from (Ginno et al., 2012). Plates were washed in ice-cold PBS (containing 1:1000 protease and phos-
phatase inhibitors) and cells were collected with a scraper and pelleted by 1500 rpm centrifugation for 5 min. Pellets were resus-
pended in 2mL lysis buffer (0.5%SDS, 5 mg proteinase K in TE, pH 8.0) and incubated on a rotating wheel overnight at 37C.Genomic
DNA was then extracted with phenol/chloroform purification and resuspended in 500 ml TE. Genomic DNA was digested with 60 U
each of BsrGI, EcoRI, HindIII, SspI and XbaI by incubating overnight at 37C. Aliquots of genomic DNA were pooled and additionally
incubated with 60 U RNase H. Digested genomic DNA was then extracted with phenol/chloroform purification and resuspended in
1 mL ChIP binding buffer (10 mM sodium phosphate, 140 mMNaCl, 0.05% Triton X-100 in TE, pH 8.0). 10 ml sample was run in a 2%
agarose gel to confirm restriction efficiency. 1% genomic DNA was collected as input control.
15 ml each of protein A and G Dynabeads per immunoprecipitation were washed three times in BSA-PBS, then added with 4 mg of
anti-DNA-RNA hybrid antibody, then incubated overnight on a rotating wheel at 4C. Beads were washed three times in BSA-PBS,
then added to genomic DNA samples and incubated overnight on a rotating wheel at 4C. Immunoprecipitates are then washed and
eluted as for ChIP. Samples were finally incubated 2 h with 2 mg proteinase K, then purified with phenol/chloroform extraction and
quantified with qPCR.
Nascent RNA analysis by 4-thiouridine (4sU) labeling
U2OS cells were treated for 2 h with 10 mMBAY-880, 1 mM pladienolide B or DMSO, then added 200 mM 4sU for 15 min (pulse), then
washed with PBS and treated in 4sU-free medium for additional 2 h (chase).
Treatment was stopped by adding Qiazol (QIAGEN). Total RNA was extracted using miRNAeasy kit according to manufacturer’s
instruction. 4sU-RNA was enriched and libraries were then prepared as previously described (Baluapuri et al., 2019). Briefly, 100 mg
RNA was first biotinylated (EZ-Link Biotin-HPDP) with 2 h rotation at RT in biotin labeling buffer (10 mM Tris pH 7.4, 1 mM EDTA).
Biotinylated RNA was cleaned up in MaXtract tubes, then pulled down using Dynabeads MyOne Streptavidin T1 beads for 15 min
at 25C with rotation. Beads were magnetically separated and repeatedly washed with wash buffer (2 M NaCl with 10 mM Tris pH
7.5, 1 mM EDTA and 0.1% Tween 20). 4sU-RNA was finally eluted using freshly prepared 100 mM DTT and cleaned using RNeasy
MinElute Spin columns.
4sU-RNA was quantified with the RiboGreen Assay and processed for cDNA library preparation using NEBNext rRNA Depletion
and Ultra RNA Library Prep kits for Illumina according to manufacturer’s instructions.
Directional RNA Sequencing
U2OSMYC-ER cells were induced with 4-OHT for 20 h with co-treatment of DMSO or 10 mMBAY-880 for the last 4 h. Treatment was
stopped by adding Qiazol (QIAGEN), then lysates were homogenized by passing them 5 times through 0.6 mm needles. RNA extrac-
tion was performed with the miRNeasy Mini Kit according to manufacturer’s instruction and using in-column DNase digestion. RNA
quality was assessed employing a Fragment Analyzer (Agilent) and directional libraries were generated using the NEBNext Ultra II
DNA Library Prep Kit for Illumina (NEB) according to manufacturer’s instructions.
RNA extraction and quantitative PCR (qPCR)
RNA extraction was performed by resuspending cells in peqGOLD Trifast, then followingmanufacturer’s instructions. cDNAwas syn-
thesized from 1 mg RNA adding M-MLV reverse transcriptase (Promega), random hexamers (Roche), dNTPs (Roth) and RiboLock
RNase Inhibitor (Thermo Fisher Scientific).
qPCR was then performed with PowerUp SYBR Green Master Mix (Thermo Fisher Scientific) on a StepOnePlus thermocycler
(Thermo Fisher Scientific) according to manufacturer’s instructions and employing the listed primers (Tables S2 and S4).
Cloning
FLAG- or HA-tagged NUAK1 vectors
A vector containing murine Nuak1 CDS was used as template for PCR with primers bearing HA or FLAG at amino- (NT) or carboxy-
terminus (CT). All NT andCT primers contained respectively also a BamHI and a EcoRI restriction site to allow for downstream cloning
in pBabe puro retroviral vectors (Table S3).
Phospho mutant PNUTS vector
pcDNA5/TO-Flag-mPNUTS, a vector containing rat Ppp1r10 CDS (a kind gift of David Skalnik, Indiana University), was used as tem-
plate for two PCRs (one for the coding region from ATG to S313, one for the one from S313 to stop codon) employing primers
with mismatches on the S313 codon designed to generate a Ser to Ala, Asp or Glu mutant (Table S3). Both PCR products (as
well as pcDNA5/TO-Flag-mPNUTS) were used as templates for a subsequent PCR with primers bearing a BamHI restriction site
at NT and a HA tag with a EcoRI restriction site at CT (Table S3). BamHI-EcoRI restriction allowed for downstream cloning in pcDNA3
vector for further transfection.
Doxycycline-inducible shNUAK1 vectors
Three NUAK1-targeting sequences selected according to (Fellmann et al., 2011) and included in the mirE backbone as previously
described. The three constructs, named mirE shNUAK1#1, #2 and #3, were then used as template for a PCR with primers bearingMolecular Cell 77, 1322–1339.e1–e11, March 19, 2020 e10
EcoRI and XhoI for subsequent cloning into the pINDUCER 11 lentiviral vector (Meerbrey et al., 2011). NUAK1-targeted sequences
are TAAGGACAAAATTAAGGATGA (#1), GCTGAAGAAATCCAAGAAAGA (#2) and TAGGGATTTACTGGCATGGTA (#3).
QUANTIFICATION AND STATISTICAL ANALYSIS
Bioinformatic analyses and statistical analyses
Fastq files were generated using Illumina’s base calling software GenerateFASTQ v1.1.0.64 and overall sequencing quality was
analyzed using the FastQC script.
For 4sU-seq, readsweremapped to the human genome (hg19) using Tophat v2.1.1 (Kim et al., 2013) andBowtie2 v2.3.2 (Langmead
and Salzberg, 2012) using the parameters –g 1 –no-coverage-search. For 4sU-Seq including NVP-2/FP, the parameters were -N 1.
Reads mapping to ribosomal rRNA (defined by UCSCs RepeatMasked table filtered for rRNA) were removed and all samples were
normalized to the sample with the smallest number of mapped reads. Bedgraph files were generated with ‘‘bedtools genomecov’’
function after removal of reads falling in exons. Reads falling into different regions of genes (exons, the first intron of a gene, all introns,
intron-spanning (‘‘spliced’’), exon-intron-overlapping, TES (defined as annotated transcriptional end site (TES) to TES+20kb), TES-
overlapping (‘‘TES-RT’’)) were filtered using the UCSC hg19 RefGene table. Reads falling into introns were normalized by the intron
length and ‘‘spliced’’ reads were normalized for the number of exons per gene. For each gene and region analyzed, the mean from
three replicates was calculated. The termination score is defined as: (TES reads + TES-RT reads) / pre-mRNA reads whereas pre-
mRNA reads are all reads falling into introns and overlapping exon-intron-boundaries. Accordingly, the splicing score is defined as:
spliced reads / pre-mRNA reads. Kernel density plots were calculated with the ‘‘density’’ function in R and a bandwidth of 0.3. 2D
Kernel density plots were generated with the ‘‘smoothScatter’’ function in R and default settings. For gene set enrichment analysis
(Subramanian et al., 2005) the splicing score for each gene was calculated for each replicate separately and the analysis was per-
formed with Signal2Noise ratio, 1000 permutations and the C5 and ‘‘Hallmark’’ gene sets from MSigDB v6.1 (Liberzon et al., 2011).
For ChIP-seq, reads were mapped to the human genome (hg19) with bowtie v1.2 (Langmead et al., 2009) and default settings.
Input samples for all biological conditions (DMSO, BAY-880, FP) were sequenced to a lower depth and combined after mapping.
Duplicated reads were removed using ‘‘samtools rmdup’’ tool (Li et al., 2009) and samples were normalized to the sample with
the smallest number of reads by randomly picking reads. For ChIP-RXseq, readswere independentlymapped to hg19 and themurine
spike-in genome (mm10) with bowtie v1.2 and default settings and a normalization factor was calculated as described previously
(Herold et al., 2019). Bedgraph files were generated with ‘‘bedtools genomecov’’ function and vizualized with the Integrated Genome
Browser (Freese et al., 2016). Peakswere calledwithMACS v1.4.2 (Zhang et al., 2008) using the input sample as control with a p value
of 1e-8. Proximity to promoters (defined as TSS +-1kb) was analyzed with bedtools ‘‘closestBed’’ function and the UCSC hg19 Re-
fSeq gene table. Average read density around the TSS (for all RefSeq listed genes), pause sites and first exon-boundary were calcu-
lated and plotted with deeptools (Ramı´rez et al., 2016) using all genes with a PNUTS peak in the promoter. The mean of all analyzed
genes is indicated by a solid line and the SEM is presented as shadow. For read density profiles, themean is shown including the SEM
as shadow. The pause site is defined by RNAPII peaks (condition EtOH/DMSO) called with MACS v1.4.2 (parameters: keep-dup 1, p
value 1e-15,–call-subpeaks) without input control to avoid standard sequencing depth normalization. Peaks in the input were called
independently with the same parameters and peaks present in the RNAPII and input sample were removed. Finally, RNAPII peaks
were annotated to RNAPII TSS and all peaks in a region of TSS to TSS+250bp were selected as viewpoint for density plots of the
pause site. ChIP-seq data for RNAPII were taken from GSE44672 (Walz et al., 2014) or GSE89384 (Olson et al., 2018) and analyzed
as described above.
For RNA-seq, reads were aligned to the human genome (hg19) using Tophat v2.1.1 and Bowtie2 v2.3. using the parameters –g 1 –n
1–library-type fr-firststrand –no-coverage-search and samples were normalized to the number of mapped reads in the smallest sam-
ple. For gene expression analysis, reads per gene (Ensembl gene database) were counted with the ‘‘summarizeOverlaps’’ function
from the R package ‘‘GenomicAlignments’’ using the ‘‘union’’-mode and non- or weakly expressed genes were removed (mean read
count over all samples < 1).
In boxplots, the central line shows themedian, the borders of the box indicate the first and third quartile and the whiskers extend to
1.5 of the interquartile range. Outliers are shown as black dots. P values comparing medians were calculated with an unpaired two-
tailed Wilcoxon rank sum test.
Statistical significance throughout experimental conditions was addressed by employing the inherent test with the Prism software
(GraphPad). P values < 0.05 were considered statistically significant.
DATA AND CODE AVAILABILITY
RNA-, ChIP- and 4sU-seq data generated for this study are available at the Gene Expression Omnibus (GEO) under accession num-
ber GSE129925.
Raw pictures (immunostainings, immunoblotting) and proteomic data are available at the Mendeley Data repository at the address
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